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A PROSPECTIVE, RANDOMIZED, PLACEO-CONTROLLED 
STUDY EVALUATING THE EFFECTIVENESS OF ORAL 
PREGABALIN AND TRAMADOL FOR POSTOPERATIVE PAIN 
MANAGEMENT IN PATIENTS UNDERGOING LUMBAR 
LAMINECTOMY 
 
ABSTRACT: 
Postoperative pain is one of the most feared problems among patients coming 
for surgery. Preventing and treating postoperative pain is a big deal despite 
recent advances in pain therapy. Opioids continue to be a cornerstone in the 
treatment of postoperative pain inspite of their side effects. Pregabalin, a 
structural analog of gamma-aminobutyric acid, has been used for the 
treatment of neuropathic pain and as an adjuvant in treating partial seizures. 
This study was thus taken up to compare the analgesic and anxiolytic effects 
of pregabalin and tramadol by administering it preoperatively in patients 
undergoing elective decompressive lumbar laminectomy. The study was 
conducted in 75 patients belonging to ASA 1 & 2 between 20 to 60 years. 
These patients were randomly allocated into three groups- group 1, 2 & 3 
containing 25 patients each. Group 1, 2 & 3 received placebo capsule, 100mg 
tramadol capsule and 150 mg pregabalin capsule respectively 1 hour before 
anaesthetic induction. Pregabalin showed stastistically significant analgesic 
and anxiolytic effect when compared to placebo but less than that of tramadol. 
Also, pregabalin was associated with less sedation than that of tramadol. 
Postoperative complications like nausea, vomiting, drowsiness was less in 
pregabalin group compared to placebo group. Also, pregabalin provided a 
stable hemodynamics throughout the intraoperative period and also prevented 
the pressor response to laryngoscopy and intubation similar to tramadol. The 
result of this study support the use of pregabalin for postoperative pain relief 
as it has fewer side effects, well tolerated and higher patient satisfaction. 
KEYWORDS: 
Pregabalin , Tramadol, postoperative pain, lumbar laminectomy.   
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INTRODUCTION 
 
Postoperative pain is one of the most feared problems among patients coming 
for surgery. 
Postoperative pain management includes pain management22, prevention and 
treatment of postoperative complications90 and restoring preoperative 
function16. 
Preventing pain and treating it is a big deal despite significant advancements 
in pain assessment and therapy2. By mobilising patients at the earliest, 
postoperative complications are reduced. It has been reported that roughly 
80% of patients undergoing surgical procedures experience postoperative 
pain2. Pain on movement is comparatively resistant to opioids than the pain 
during rest91 and can lead to postoperative pulmonary49, cardiac33, and 
thromboembolic complications63, 56, 15. 
The guidelines for postoperative pain treatment has been revised and drugs 
like S-ketamine, pregabalin, metamizole, oxycodone are used as new methods 
of preventing postoperative pain.45 
Prolonged chronic pain after surgery has been under recognised until recently 
which is actually a very common phenomenon. 
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A number of risk factors and predictors including the age, gender, surgical 
procedure, pre and postoperative pain, genes, psychosocial factors and pain 
modulation variables have been identified. 
Together with an increased knowledge about the pathophysiology of chronic 
pain after surgery it may be possible to develop successful drugs and 
interventions in the near future.  
Post-surgical pain is normally perceived as nociceptive pain. Surgical trauma 
causes central and peripheral sensitization and hyperalgesia which when 
untreated can lead to chronic postoperative pain after surgery. 
Indeed pain is one among the three most common causes of delayed discharge 
after ambulatory surgery next to drowsiness and nausea/vomiting. 
Antihyperalgesic drugs improve the postoperative pain by preventing the 
development of central sensitisation.99 
The recent advance in postoperative pain management includes finding out 
the exact mechanism of action of drugs at molecular level, newer routes and 
modes of analgesic delivery. 
For years opioids have been the cornerstone of postoperative pain 
management inspite of their side effects. Hence the search for newer 
analgesics and combination of analgesics and other non-opioid drugs 
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continues in order to improve postoperative analgesia and reduce opioid 
related side effects.3 
In this context, the gabapentinoids (gabapentin and pregabalin) have been 
extensively studied. 
Gabapentinoids were successfully used in the treatment of trigeminal 
neuralgia, diabetic neuropathy, post herpetic neuralgia46, 14, 57, 77, 51, 18. In 
addition their usefulness for postoperative pain relief is also studied55, 7 
 The present study was thus taken up to test the efficacy of pregabalin for pain 
management in lumbar laminectomy. 
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AIMS AND OBJECTIVES 
 
AIM: 
The aim of my study is to assess and compare the efficacy and safety of 
preoperative administration of pregabalin and tramadol in patients undergoing 
elective lumbar laminectomy. 
 
OBJECTIVES: 
 To measure the analgesic, anxiolytic and sedative effects by VAS score, 
anxiety score and Ramsay sedation score respectively. 
 To evaluate the intraoperative hemodynamics. 
 To assess their adverse effects. 
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PAIN PATHWAYS AND THE NEUROBIOLOGY OF 
NOCICEPTION 
 
The physiological processes involved in nociception are 
1. Transduction- process by which a noxious stimuli produced by tissue injury 
gets converted into electrical signals. It occurs in nociceptors (Free endings of 
Aδ and C fibres). 
2. Transmission – process of pain impulse transmission by the nociceptors 
from periphery to the spinal cord and then to thalamus and finally to the 
cerebral cortex. Aδ and C fibres, spinothalamic and spinoreticular tracts are 
involved in this. 
3. Modulation- process by which pain impulses produced are either inhibited 
or facilitated. It occurs peripherally in nociceptors and also in dorsal horn of 
the spinal cord and supraspinal structures. 
4. Perception – process by which pain produces conscious multidimensional 
experience. Areas of cortex involved are the reticular system, somatosensory 
cortex and the limbic system. 
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Figure 3.1 Pain pathway and physiology 
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Surgery produces tissue injury which results in release of histamine and 
inflammatory mediators such as peptides (e.g., bradykinin), lipids (e.g., 
prostaglandins), neurotransmitters (e.g., serotonin), and neurotrophins (e.g., 
nerve growth factor)51. This activates the peripheral nociceptors, which 
initiate transduction and transmission of nociceptive information to the central 
nervous system (CNS) as well as the process of neurogenic inflammation in 
which release of neurotransmitters (substance P and calcitonin gene–related 
peptide) in the periphery causes vasodilatation and plasma extravasation.51 
Noxious stimuli are transduced by peripheral nociceptors and then transmitted 
by Aδ and C nerve fibres from peripheral somatic and visceral sites to the 
dorsal horn of the spinal cord, where integration of peripheral nociceptive and 
descending modulatory input (i.e., norepinephrine, serotonin, encephalin, 
γ­aminobutyric acid) occurs. Further transmission is determined by complex 
modulating influences in the spinal cord. Some impulses pass to the ventral 
and ventrolateral horns which initiate segmental (spinal) reflex responses, that 
may be associated with inhibition of phrenic nerve function, increased 
skeletal muscle tone, or even decreased gastrointestinal motility while others 
are transmitted to higher centres through the spinoreticular and spinothalamic 
tracts where they induce cortical and suprasegmental responses to ultimately 
produce the perception of and affective component of pain. Continuous 
release of inflammatory mediators in the periphery causes sensitization of 
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functional nociceptors and activates dormant ones.18 Sensitization of 
peripheral nociceptors leads to decreased threshold for activation, increased 
rate of basal (spontaneous) discharge and increased rate of discharge with 
activation.18 It may also result in central sensitization (“persistent postinjury 
changes in the CNS that result in pain hypersensitivity”)55 and hyperexcit­ 
ability (“exaggerated and prolonged responsiveness of neurons to normal 
afferent input after tissue damage”).55 Such noxious input may cause 
functional changes in the dorsal horn of the spinal cord  which may later on  
cause postoperative pain to be perceived as more painful than it would have 
been. Thus the neural circuitry in the dorsal horn is extremely complex. 
However, it seems that certain receptors (e.g., N­methyl­d­aspartate 
[NMDA]) may be especially important and the second messenger effectors 
(e.g., substance P, protein kinase C) may also play important roles in spinal 
cord sensitization and development of chronic pain after acute pain.7 Thus 
from the hard­ wired system proposed by Descartes in the 17th century our 
current understanding of neurobiology of nociception has travelled to a new 
dimension of neuroplasticity in which modulation and dynamic integration  of 
nociceptive transmission take place at several levels. Still our knowledge is 
deficit regarding the specific roles of various neurotransmitters, receptors, and 
molecular structures in the process of nociception.  
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 The traditional dichotomy between acute and chronic pain is arbitrary and 
studies demonstrate that  transition is quick from acute to chronic pain.18 
Experimental studies show that noxious stimuli can produce expression of 
new genes (which forms the basis of neuronal sensitization7) in the dorsal 
horn of the spinal cord within 1 hour and which are sufficient enough to alter 
behaviour within the same duration.9 Clinical studies also suggest that the 
intensity of acute postoperative pain is a significant predictor of chronic 
postoperative pain.71 Thus preventive analgesia and multimodal analgesia 
may be important in facilitating short as well as long-term patient 
convalescence after surgery. 
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ACUTE AND CHRONIC EFFECTS OF POSTOPERATIVE PAIN 
ACUTE EFFECTS58, 113, 25 
Emotional and physical suffering 
Sleep disturbance 
Cardiovascular system: tachycardia, hypertension, increased oxygen 
consumption, myocardial ischemia, deep venous thrombosis 
Respiratory system: decreases lung volumes, impairs cough, sputum 
retention, infection, atelectasis 
Gastrointestinal system: reduces bowel motility 
Genitourinary system: urinary retention 
Central nervous system: anxiety 
Endocrine system: increases catabolic hormones, increases blood glucose, 
causes sodium and water retention 
Immunological impairment, infection, delayed wound healing. 
Control of acute postoperative pain may attenuate the sympathetic outflow, 
stress response, inhibitory spinal reflexes and contribute to improvements in 
patient morbidity, mortality and outcomes (health- related quality of life 
[HRQL], patient satisfaction). 
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CHRONIC EFFECTS: 
Risk of development of chronic pain 
Risk of behavioural changes especially in children 
Delay in long term recovery. 
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PREVENTIVE ANALGESIA 
 
The concept of pain prevention was first introduced by Crile in 191324 and 
later developed by Wall96 and Wolf100. 
Central sensitization and hyper excitability develop after surgical incision 
which results in amplification of postoperative pain. 
Preventing the establishment of altered central processing by analgesics may 
result in short and long term benefits for the patient during convalescence.16 
 
DEFINITION: 
Definitions of pre-emptive analgesia include what is administered before the 
surgical incision, what prevents the establishment of central sensitization 
resulting from incisional injury only(i.e., intraoperative period), what prevents 
central sensitization resulting from incisional and inflammatory injury(i.e., 
intraoperative and postoperative periods), or the entire perioperative period 
encompassing preoperative interventions, intraoperative analgesia, and 
postoperative pain management(i.e., preventive analgesia).55 
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SCIENTIFIC RATIONALE: 
As already discussed above, tissue damage detected by free nerve endings 
(peripheral nociceptors) are transduced by them and transmitted by Aδ and C 
fibres to the dorsal horn of spinal cord. 
The myelinated Aδ fibres conduct rapid, sharp and well localised pain called 
the first pain. Unmyelinated C fibres conduct duller, slower and poorly 
localised pain called the second pain. 
The dorsal horn consists of two groups of neurons. Nociceptive specific (NS) 
neurons respond only to noxious stimuli from Aδ and C fibres. Wide dynamic 
range (WDR) neurons respond to both noxious stimuli and non- noxious 
stimuli from Aβ fibres (touch). Activity of WDR neurons depend on 
excitatory and inhibitory input from nociceptive and non- nociceptive 
peripheral nerve fibres and descending input from supraspinal sites. 
Tissue damage during surgery results in conduction of noxious stimuli from 
nociceptors to dorsal horn neurons (NS and WDR) which results in altered 
responsiveness of these neurons. 
Stimuli from Aδ and C fibres are amplified (i.e.,) hyperalgesia and stimulus 
from Aβ fibres are misinterpreted (i.e.,) allodynia. This is central 
sensitization. 
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Pre-emptive analgesia may help to prevent the neurological and biochemical 
consequences of noxious input to central nervous system. 
 
 
 
 
Figure 4.1 Pathophysiology of pain  
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MULTIMODAL APPROACH TO PERIOPERATIVE 
RECOVERY 
 
Kehlet and Dahl were the first to describe the concept of combining multiple 
analgesic techniques in 199372 
By applying multimodal strategy the analgesic benefits of controlling 
postoperative pain are generally maximised and opioid related adverse effects 
are reduced. 
Multimodal analgesia is achieved by combining different analgesics that act 
by different mechanisms at different sites in the nervous system such that 
adequate analgesia is attained with lower doses and reduced incidence of side 
effects. 
To attain maximum benefit pain management must be initiated in the 
preoperative period, continued intraoperatively and in the postoperative 
period. 
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BENEFITS 
Effective analgesia due to synergistic action. 
It is useful in patients at risk for larger doses of opioids such as elderly, 
obstructive sleep apnoea and chronic pain patients. 
Fewer side effects due to lower dosage of drug used. 
Faster recovery. 
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GABAPENTINOIDS IN PAIN MANAGEMENT 
 
Gabapentinoids (Pregabalin and Gabapentin) were originally introduced as 
antiepileptic but they also have analgesic, anticonvulsant and anxiolytic 
effects. 
These drugs are easily tolerable and have limited side effects 
 
GABAPENTIN 
Gabapentin binds to the α-2 delta subunit of the presynaptic voltage gated 
calcium channel, inhibits the release of calcium, thereby preventing the 
release of excitatory neurotransmitters involved in the pain pathways.3, 44 
 
Gabapentin has demonstrated the analgesic effect in postherpetic neuralgia, 
diabetic neuropathy and neuropathic pain. 
 
It produces a significant opioid sparing effect and decreases post-operative 
pain score relative to control group.60, 86 
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PREGABALIN 
Pregabalin is a structural analog of GABA (gamma amino- butyric acid). 
Pregabalin acts by presynaptic binding to the α-2λ subunit of the voltage 
gated calcium channel. 
These channels are widely distributed in brain and the spinal cord.31 
By binding to the calcium channels, pregabalin modulates the release of 
several excitatory neurotransmitters like norepinephrine, glutamate, 
substanceP, and calcitonin gene – related peptide.  
This leads to inhibitory modulation of “overexcited neurons” and returns them 
back to their “normal” state. 
It also reduces the hyperexcitability of dorsal horn neurons that is induced by 
tissue damage.31 
To sum up, pregabalin has a more appropriate pharmacological profile than 
gabapentin, including dose dependent absorption and far more potent than 
gabapentin while producing fewer adverse effects29, 38, 64 
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PHARMACOLOGY OF PREGABALIN30, 8 
 
Pregabalin belongs to the gabapentenoid group of drugs. It possesses 
chemical structure similar to inhibitory neurotransmitter GABA (gamma 
amino butyric acid). Pregabalin has got similar properties like the prototype 
drug gabapentin. 
 
Figure 7.1 Chemical structure of Pregabalin 
 
Pregabalin which is chemically S-(+)-3-isobutylgaba (Fig-7.1), was designed 
as a lipophilic analogue of GABA (gamma-amino butyric acid) substituted at 
the 3-position to facilitate diffusion across blood brain barrier. 3-isobutylgaba 
exists in isomeric forms, rendering the drug pharmacologically active 
enantiomer. 
20 
 
DRUG APPROVAL30 
July 2004–European Commission, granted the pharmaceutical company 
Pfizer, approval for pregabalin for the treatment of peripheral neuropathy and 
as an adjunctive therapy for partial seizures in patients with epilepsy. 
 
December 2004-The Food and Drug Administration (FDA) approved 
pregabalin, for the treatment of neuropathic pain associated with diabetic 
peripheral neuropathy and post herpetic neuralgia.  
 
June 2005-The FDA approved pregabalin for use as an adjuvant in partial 
seizure treatment. 
 
March 2006- Pregabalin got approval from European commission, for the 
treatment of generalised anxiety disorder  
 
Pregabalin is placed in Schedule V of the controlled substance act, based on 
the report of euphoria in controlled clinical trials. 
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MECHANISM OF ACTION 
Pregabalin is only structurally related to the inhibitory neurotransmitter 
GABA. It neither acts on GABA receptor, nor mimics it physiologically. The 
precise mode of action of pregabalin has not been fully elucidated. Pregabalin 
has got similar pharmacological profile as gabapentin. The main site of action 
of pregabalin is on the alpha 2 delta subunit of neuronal calcium channels. 
 
PREGABALIN- AN ALPHA 2 DELTA LIGAND17 
Alpha 2 delta is a subunit of presynaptic, voltage-gated calcium channel. The 
main site of action of pregabalin is this alpha 2 delta subunit of neuronal 
calcium channels. This binding reduces the depolarisation induced calcium 
influx at nerve terminals. As a consequence, there is reduction in the release 
of several excitatory aminoacids like glutamate, noradrenaline, substance-P, 
and CGRP (Calcitonin Gene Regulated Peptide). This modulation of 
neurotransmitter release by pregabalin contributes to its anticonvulsant, 
anxiolytic, and analgesic property. 
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Voltage gated calcium channels are divided into six types P, Q, N, L, R, and 
T-type channels. N-type calcium channels are involved in pain sensitization 
phenomenon in response to noxious stimuli. Calcium channel blockers like 
nifedipine binds to L-type channels, whereas pregabalin binds to N-type. 
Cardiac and other peripheral tissues have L-type calcium channels. This 
explains the lack of cardiovascular side effects with pregabalin. 
 
 
 
 
 
 
 
 
Figure 6.2 Structure of calcium channel 
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DOSAGE AND ADMINISTRATION 
For painful diabetic peripheral neuropathy, the maximum recommended 
dosage is 100 mg thrice a day. Because pregabalin is eliminated primarily by 
renal excretion, the dose needs to be reduced in patients with reduced renal 
function. For peripheral neuropathy, dosing should begin at 75 mg per day, 
and may be increased to 300 mg per day within a week based on efficacy and 
tolerability. 
 
PHARMACOKINETICS 
Pregabalin has consistent and dose proportionate pharmacokinetics. The mean 
elimination half-life of pregabalin is 6.3 hours, and is independent of dose and 
repeated administration. This consistent dose-proportional pharmacokinetics 
of pregabalin provides confidence in the prediction of dose-response 
relationship in clinical practice. Administration of pregabalin with food has 
no effect on its absorption13. 
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DISTRIBUTION, METABOLISM, ELIMINATION 
L-transporter is an important system which is responsible for the transport of 
substances across the brain and gut. Pregabalin is a substrate of this system 
and hence crosses blood brain barrier rapidly. This property is essential for a 
drug that influences central nervous system activity. 
 
In humans, pregabalin undergoes less than 2% metabolism. It is excreted 
unchanged by the kidneys. In patients with compromised renal function the 
dose of pregabalin needs to be reduced. In patients with creatinine clearance 
between 30 to 60 ml/minute, daily dose of pregabalin needs to be reduced by 
50% when compared to patients with creatinine clearance more than 60 
ml/minute. 
 
PREGABALIN VERSUS GABAPENTIN 
Though pregabalin and gabapentin belongs to same group and possesses 
similar chemical structure, pregabalin has better pharmacokinetic properties 
as discussed previously. 
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Table 7.1 Pharmacological properties of pregabalin8 
Property Clinical significance 
 
1. High affinity for α2δ receptor 
2. No effect on GABA  
3. Linear dose proportional Cmax 
4. Lack of protein binding 
5. Negligible metabolism 
6. Renal excretion (98% unchanged) 
 
7. Rapidly cross blood brain barrier  
 
New mechanism of action 
No retinal or optic nerve toxicity 
Predictable level and dose response 
No drug interactions 
No drug interactions  
Dose reduction in renal impairment 
No hepatic effects 
Access to CNS site of action 
 
Cmax- maximum plasma concentration 
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PREGABALIN LACKS DRUG - DRUG INTERACTIONS 
Pregabalin does not bind to plasma proteins and is not subjected to hepatic 
metabolism. Studies done on human liver microsomes have demonstrated that 
pregabalin does not affect the cytochrome P450 system. 
These facts indicate that pregabalin is unlikely to cause pharmacokinetic drug 
interactions. This property is important when administering pregabalin with 
other anticonvulsant drugs. 
 
SAFETY IMPLICATIONS 
Pregabalin does not completely block calcium channel function or transmitter 
release, even at high concentration. This property could have important safety 
implications in case of drug overdose. Alpha 2 delta ligands acts on N-type 
calcium channels, and have little effect on voltage gated calcium channels of 
heart(L-type), or other peripheral tissues. Hence, pregabalin has no effect on 
arterial blood pressure or cardiac function at therapeutic doses. 
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CLINICAL USES 
Highly effective adjunctive therapy in the treatment of partial seizures 
Chronic pain syndromes like, diabetic peripheral neuropathy, and post 
herpetic neuralgia. 
Chronic anxiety disorder. 
Adjuvant in acute pain management. 
 
Since pregabalin possess anticonvulsant, sedative, analgesic, and anti-
hyperalgesic properties, studies are being done on potential perioperative uses 
like pre-operative sedation, anxiolysis, reduced intraoperative opioid 
requirement, and attenuation of hemodynamic stress response to laryngoscopy 
and tracheal intubation. 
Alpha 2 delta receptor seems to be involved in the phenomenon of neuronal 
hypersensitisation to noxious stimuli. Blunting of this hypersensitisation by 
pregabalin helps in reducing the intensity of post-operative pain and has got 
opioid sparing effect. 
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SIDE EFFECTS AND PRECAUTIONS 
Pregabalin is a well-tolerated, relatively safe drug with dose-dependent 
adverse effects which are mild to moderate and usually transient. 
1. Dizziness (29%) 
2. Somnolence (22%) 
3. Dryness of mouth (9.1%) 
4. Blurred vision (6.4%) 
5. Edema (6.1%) 
6. Weight gain (5.6%) 
7. Abnormal thoughts (5.4%) 
There are case reports of myoclonus, gynaecomastia, and a single case report 
of carpus callosum edema. Withdrawal of pregabalin after long term therapy 
should be gradual as it may potentiate seizure activity. 
Pregabalin is contraindicated in patients with history of allergy to the drug or 
any of its components. FDA placed pregabalin in class C for pregnant 
patients. It is not recommended in pregnancy and breast feeding. Dose needs 
to be reduced in patients with reduced renal function. 
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PHARMACOLOGY OF TRAMADOL 
 
Tramadol is a centrally acting atypical opioid with additional serotonin- 
norepinephrine reuptake- inhibitory action.36 
It is marketed as a racemic mixture of both R- and S- enantiomers as they are 
known to complement each others analgesic efficacy. It is called an atypical 
opioid because apart from being a serotonin reuptake inhibitor it is a fairly 
weak µ-opioid receptor agonist. 
CHEMICAL SRUCTURE OF TRAMADOL 
(1R, 2R)- tramadol ; (1S, 2S)- tramadol                 
 
 
Figure 8.1 Chemical structure of Tramadol  
30 
 
Tramadol is chemically [2-(dimethylaminomethyl)-1-(3-methoxyphenyl) 
cyclohexanol]. Tramadol has two stereogenic centres at the cyclohexane ring. 
Thus it may exist in four different configurational forms. 
(1R,2R)-isomer 
(1R,2S)-isomer 
(1R,2S)-isomer 
(1S,2R)-isomer 
 
DRUG APPROVAL39-42 
March 1995- FDA approval for treatment of moderate to moderately severe 
pain. 
September 2005- FDA approval for extended release formulation 
May 2005- FDA approval of Tramadol for orally disintegrating form for 
treatment of moderate to moderately severe pain. 
August 2014- Tramadol has been placed into schedule IV of the federal 
Controlled Substances Act. 
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MECHANISM OF ACTION42, 30, 26, 39, 66, 79, 59, 80, 78 
Tramadol acts as a µ- opiod receptor agonist, serotonin releasing agent, 
norepinephrine reuptake inhibitor. 
It is also an NMDA receptor antagonist, 5- HT2C receptor antagonist, nicotinic 
acetyl choline receptor agonist, transient receptor potential cation channel 
(TRPV1) and M1 and M2 muscarinic acetylcholine receptor antagonist. 
Tramadol has inhibitory action on 5- HT2C receptor which could be partially 
responsible for tramadol’s reducing effect on depressive and obsessive- 
compulsive symptoms in patients with pain and comorbid neurological 
illness. It may also be responsible for its seizure lowering threshold. However, 
it may also be attributed to tramadol’s putative inhibition of GABAA receptors 
at high doses.  
The metabolite, O- desmethyltramadol, is a high affinity ligand of δ- and κ- 
opioid receptors and δ- opioid receptor agonism is well known to induce 
seizures. 
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DOSAGE AND ADMINISTRATION72 
It can be administered by oral, intravenous, intramuscular and rectal routes. 
It can be administered either as 50mg or 100mg every 4 to 6 hours not 
exceeding the dosage of 400mg per day. 
 
PHARMACOKINETICS11,72 
Tramadol has a linear pharmacological profile within the therapeutic range. 
Absorption: 
Tramadol is almost completely and rapidly administered after oral 
administration. Maximum plasma concentration (Cmax) is reached two hours 
after oral administration. The mean serum concentration after intravenous 
injection is 1.46 times higher than that of oral administration. Tramadol can 
be administered without regard to food. 
 Its bioavailability in oral route is 70-75%, for rectal it is 77% and 100% for 
intramuscular route 
Distribution: 
Tramadol is rapidly distributed in the body with a volume of distribution of   
2-3 L/kg . It is reduced by 25 percent in those aged above 75 years. Plasma 
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protein binding is about 20 percent. Tramadol crosses the placental and blood 
brain barriers. 
Metabolism: 
Tramadol undergoes hepatic metabolism. It involves demethylation and 
glucuronidation via cytochrome P450 isozymes and metabolised to five 
different metabolites. Of these O- desmethyltramadol has 200 times affinity to 
µ- opioid receptor. Further, it has a elimination half- life of nine hours while 
that of tramadol is only six hours. 
Phase II hepatic metabolism results in water- soluble metabolites which are 
then excreted by the kidneys. Thus, in renal and hepatic impairment doses 
may be reduced. 
Excretion: 
Tramadol and its metabolites are excreted mainly by kidneys (95%). 
Approximately 15- 19% of an administered dose is excreted as unmetabolised 
drug which increases in elderly to about 35%. 
Tramadol has a half-life of 5-7 hours whreas its metabolite O- desmethyl 
tramadol has a half-life of 6-8 hours. 
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DRUG INTERACTIONS72, 76, 52 
Potentially fatal drug interactions occur with drugs such as serotonergics, 
monoamine oxidase inhibitors, selective serotonin reuptake inhibitors, 
serotonergic antidepressants, certain analgesics (pethidine, oxycodone, 
dextromethorphan, fentanyl) .certain antibiotics (linezolid, isoniazid), certain 
anxiolytics,amphetamines, phenethylamine, lithium, methylene blue and a lot 
other therapeutic agents. Any agents that either induce or inhibit cytochrome 
P450  are likely to interact with tramadol as it is a substrate of these enzymes. 
 
CLINICAL USES OF TRAMADOL76, 52, 76, 38, 19 
Tramadol is used in the treatment of moderate to moderately severe pain in 
both acute and chronic setting.  
The European League Against Rheumatism has recommended its use for the 
management of pain fibromyalgia. 
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INVESTIGATIONAL USES40, 41, 76, 36, 11, 82, 84, 101,98, 81 
Diabetic neuropathy 
Antidepressant 
Postherpetic neuralgia 
Acute opioid withdrawal syndrome 
Obsessive-compulsive disorder 
Premature ejaculation 
Post- traumatic stress disorder  
 
ADVERSE EFFECTS72,81, 48, 10, 13, 75 
Very common: (>10% frequency) 
Dizziness 
Nausea 
Vomiting 
Constipation 
Headache 
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Somnolescence 
 
Common:(1-10% frequency) 
Anxiety 
Dyspepsia 
Pruritus 
Dry mouth 
Malaise 
Urinary retention 
Visual disturbance 
Miosis 
Spasticity 
Sleep disorder 
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Uncommon: (0.1-1% incidence) 
Palpitation 
Tachycardia 
Postural hypotension 
Gastrointestinal irritation 
Urticaria 
Flushing 
Retching 
 
Rare: (0.01-1% incidence) 
Bradycardia 
Hypertension 
Dyspnoea 
Tinnitus 
Migraine 
Anaphylaxis 
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Hallucinations 
Respiratory depression 
Epileptiform convulsions 
Stevens – Johnson syndrome 
Hepatitis 
Liver failure 
Pulmonary edema 
Gastrointestinal bleeding 
Pulmonary embolism 
Myocardial ischaemia 
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REVIEW OF LITERATURE 
 
There are a lot of studies on search for newer drugs apart from opioids for 
postoperative main management. 
 
Shnekar BF et al.81 reviewed other studies regarding pregabalin’s 
pharmacology, pharmacokinectics, efficacy and adverse effects in the 
treatment of neuropathic pain, epilepsy and anxiety. Abstracts from 
professional meetings were also included. They concluded that pregabalin is 
effective and safe analgesic, antiepileptic and also an anxiolytic. It will 
provide a new treatment option for patients with neuropathic pain and partial 
epilepsy. 
 
Tassone DM et al.83 reviewed four clinical trials conducted on pregabalin. 
They finally concluded that pregabalin appears to be effective in treatment of 
patients with diabetic neuropathy, postherpetic neuralgia and adults with 
refractory partial-onset seizures. It may also be beneficial in adult patients 
with general anxiety disorder or social anxiety disorder. 
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Jokela R et al.48 conducted a randomized controlled trial of perioperative 
administration of pregabalin for pain relief after laparascopic hysterectomy. In 
this study, they evaluated the control of pain after perioperative 
administration of pregabalin 300 or 600 mg. 91 patients scheduled for 
laparascopic hysterectomy were randomized to receive either diazepam 10mg, 
pregabalin 150mg or pregabalin 600 mg as premedication and the dose was 
repeated after  12 hours except the diazepam group where they received 
placebo. Until the first postoperative morning, analgesia was provided by 
oxycodone using patient controlled analgesia. This study concluded that 
perioperative administration of pregabalin 600mg decreases oxycodone 
consumption compared with diazepam 10mg but is associated with an 
increased incidence of side effects. 
 
Burke SMet al.70 conducted a study in which they evaluated the advantage of 
perioperative administration of pregabalin in patients undergoing lumbar 
discectomy. In this study, forty patients were randomly allocated into two 
groups. They either received placebo or pregabalin. VAS score and the Mc 
Gill pain Questionaire were noted from preoperatively to 3 months 
postoperatively. The Roland Morris disability score at the end of 3 months 
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was less in patients who received pregabalin and the decrease in VAS score 
was also greater in patients who received pregabalin rather than placebo. 
Pregabalin administration was associated with greater pain tolerance in both 
the lower limbs than placebo at 24 hours postoperatively. Pregabalin, a 
membrane stabiliser, may decrease central senitization and subsequent 
peripheral pain. Thus perioperative pregabalin administration is associated 
with less pain intensity and improved functional outcomes 3 months after 
lumbar discectomy. 
 
Buvanendran A12 et al. in their study investigated whether a single 300mg 
dose of pregabalin in patients has sufficient central nervous system 
bioavailability to be useful under acute conditions where brain or spinal cord 
excitability may lead to long-term disease, such as chronic pain. Nine patients 
undergoing total knee replacement received pregabalin 300 mg orally 1 hour 
before surgery. An intrathecal catheter was inserted for anaesthesia, 
postoperative analgesic drug administration, and for cerebrospinal fluid 
sampling. Pregabalin concentration in CSF and plasma was measured using a 
validated high-pressure liquid chromography assay. It was found that 
pregabalin concentration in CSF was high 2 hours after administration to have 
anticonvulsant activity and after 6 hours its high enough to reduce central 
nervous system hypersensitivity. The median time to peak pregabalin 
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concentration in CSF was at 8 hours. The study concluded that sufficient 
central nervous system concentration are reached after oral administration of 
pregabalin, suggesting that postoperative pain hypersensitivity can be 
reduced. As this acute pain or spinal cord excitability is decreased, it may 
prevent chronic pain from developing after surgery. 
 
Jo HR et al.47 designed a study to confirm whether remifentanil given during 
propofol anaesthesia induced postoperative pain sensitization and pregabalin 
given could prevent this pronociceptive effect. Patients were randomly 
allocated into three groups. The control group received placebo and 
intraoperative saline infusion, second group received placebo as 
premedication and an intraoperatuve infusion of remifentanil, the third group 
received pregabalin 150 mg as premedication and remifentanil infusion.VAS 
scores as well as postoperative opiod requirement were noted. The results of 
this study shows that remifentanil added to propofol  anaesthesia causes pain 
sensitization in the immediate postoperative period. Pretreatment with 
pregabalin prevents this pronociceptive effect and so this may be useful for 
the management of acute postoperative pain when remifentanil and propofol 
are used as anaesthetics. 
43 
 
Choi YS et al.20 conducted a study using a combination of pregabalin and 
dexamethasone for evaluating the postoperative pain and functional outcome 
in patients undergoing lumbar spinal surgery. In this randomised-controlled 
study,one hundred and eight patients were randomised into three groups. 
Group C received placebo+placebo, group P received pregabalin+placebo and 
group PD received pregbalin+dexamethasone. The pain intensity and side 
effects were assessed in the postoperative period upto 72 hours. Pain intensity 
and  daily activity performance were also assessed 1, 3 and 6 months after 
surgery. Compared to group C, the pain scores were  lower in group PD 24 
hours after surgery and the frequency of additional rescue doses were 
significantly lower in group PD until 48 hours after surgery. The same were 
lower in group P for 24 to 48 hours relative to group C. Daily activity 
performance was better in group PD compared with group C at 1 month after 
surgery. This study concludes that combined administration of pregabalin and 
dexamethasone conferred analgesic benefits superior to those of pregabalin 
alone. Further it also facilitated the return to normal activity after surgery. 
 
Joshi SS et al.50 conducted a study evaluating the efficacy of perioperative 
pregabalin on acute and chronic postoperative pain after off-pump coronary 
artery bypass (OPCAB) surgery. Patients were randomised to pregabalin and 
control groups. Pregabalin group received 150mg pregabalin 2 hours prior to 
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induction of anaesthesia and 75 mg twice daily for two postoperative days 
whereas the control group received placebo at similar timings. VAS score and 
sedation score were observed upto 48 hours after extubation. Time to 
extubation, tramadol consumption and side effects were also noted. The study 
concluded that perioperative pregabalin reduced pain scores at rest and deep 
breath and also reduced the consumption of tramadol in the post operative 
period without causing any delay in extubation or excess sedation.  
 
Garcia RM et al.31 conducted a study to assess the efficacy of a novel 
multimodal analgesic regimen in reducing postoperative pain and intravenous 
morphine requirements after primary multilevel lumbar laminectomy. 22 
patients were randomly assigned to receive either only intravenous morphine 
or a multimodal analgesic regimen (celecoxib, pregabalin, extended release 
oxycodone). Postoperatively all patients received intravenous morphine as 
and when needeed.VAS scores upto 36 hours and total  morphine requirement 
were noted. Patients demonstrated lower intravenous morphine requirements, 
better pain score and earlier time to solid food intake. The study concluded 
that opioid and nonopioid combinations appear to be safe and effective after 
lumbar laminectomy. 
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In their study, Balaban F et al.22 analysed the efficacy of two different doses 
of preoperative pregabalin (150 mg and 300 mg) on pain relief and total 
opioid consumption after laparascopic cholecystectomy. Postoperative VAS 
scores, Ramsay sedation score and Aldrette scores were measured upto 24 
hours after surgery. Additional opioid requirement and side effects if any, 
were also noted. The results of this study showed that preemptive pregabalin 
decreased pain scores and postoperative fentanyl requirement in patients 
undergoing laparascopic cholecystectomy in a dose dependent manner. There 
was also no difference in side effects between the two different groups on two 
different dosages. 
 
George RB et al.33 performed a study to determine if low dose of pregabalin 
could decrease opioid use following abdominal hysterectomy while 
comparing placebo.   Patients were randomised into three groups- pregabalin 
75 mg (P75), pregabalin 150 mg (P150) or placebo. The study drug was 
administered two hours prior to surgery and 12 hour following the initial 
dose. Postoperative pain was managed using patient controlled analgesia with 
morphine. Pain at rest and movement as well as complications like 
nausea,vomiting were also assessed. Mean cumulative morphine consumption 
postoperatively was noted. This clinical trial showed pregabalin treatment 
may not be use in reducing opioid use upto 24 hours postoperatively. 
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Meet JM et al.61 conducted a study in which patients undergoing 
photorefractive keratectomy were given pregabalin 75mg twice daily for five 
days whereas the control group received placebo. Both groups received the 
standard pain care regimen. It was found that in pregabalin group there was 
lower pain scores and the frequency of rescue pain medications were also 
low. 
 
Aydogan H et al.4 conducted a study by administering a single oral dose of 
75mg of pregabalin to patients undergoing percutaneous nephrolithotomy. 
They evaluated the effect of pregabalin on postoperative pain scores, 
analgesic consumption and side effects. They found that pregabalin is 
effective in reducing early postoperative pain scores and total analgesic 
consumption without any hemodynamic instability or side effects. 
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MATERIALS AND METHODS 
 
After obtaining institutional ethical commmitee approval and informed 
consent, the study was conducted in 75 patients belonging to American 
Society of Anaesthesiology- 1 (ASA) and ASA- 2 of either sex and age group 
between 20-60 years  undergoing elective decompressive lumbar 
laminectomy. 
 
This a prospective, randomised, single blinded study. 
 
The study was conducted in Rajiv Gandhi Government General Hospital, 
Madras Medical College. 
 
The patients were randomised into three groups of 25 patients each by closed 
envelope method. The patients were blinded to the group they belong. 
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INCLUSION CRITERIA 
Age – 20 years to 60 years 
Weight - 40 to 70 kilograms 
BMI - < 30 kilograms/metre square 
ASA- 1 & 2 
Surgery- elective lumbar decompressive laminectomy 
Patients who have given valid informed written consent. 
 
EXCLUSION CRITERIA 
Patients not satisfying inclusion criteria 
Patients posted for emergency surgery 
Patients with renal insufficiency 
Patients with liver disease 
History of allergy or sensitivity to the drugs used 
History of seizure disorder 
Chronic therapy with opioids. 
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PRIMARY AND SECONDARY OUTCOME 
The primary outcome of the study was to measure the analgesic and 
anxiolytic efficacy of pregabalin and tramadol for postoperative pain while 
the secondary outcome was to assess the intraoperative hemodynamics and 
adverse effects of these drugs. 
 
MATERIALS 
Pregabalin capsules 150mg 
Tramadol capsules 100mg 
Placebo capsules 
Drugs- Injection Midazolam, Injection Glycopyrrolate, Inj Fentanyl,  
Inj.Thiopentone Sodium, Inj. Vecuronium, Inj. Neostigmine, Sevoflurane, 
emergency drugs, Normal Saline and Ringer Lactate. 
Monitors- ECG, NIBP, SPO2, EtCo2. 
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STUDY DESIGN 
The patients satisfying inclusion criteria were randomly allocated into three 
groups each containing 25 patients. Randomisation was done by closed 
envelope method. 
Group 1(placebo)- received a placebo capsule orally 1 hour before anaesthetic 
induction. 
Group 2 (tramadol)- received a tramadol capsule 100mg orally 1 hour before 
anaesthetic induction. 
Group 3(pregabalin)- received a pregabalin capsule 150mg 1 hour before 
anaesthetic induction. 
All patients were visited the evening before surgery. They were explained 
about the study methods, the visual analogue scale chart and were provided 
with information sheet. All were orally premedicated with alprazolam 0.5mg 
at 10.00 pm, the previous night of surgery. 
 
ANAESTHESIA PROTOCOL 
The patients were premedicated with an injection of midazolam (0.05mg/kg) 
i.v. and an injection of glycopyrrolate (0.005mg/kg) i.v. Analgesia was 
provided with Injection fentanyl 2mic/kg and induction was done with 
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thiopentone sodium (5 mg/kg of 2.5% solution).Endotracheal intubation was 
facilitated by using vecuronium bromide as muscle relaxant in the dosage of 
0.1mg/kg. Anaesthesia was maintained with N2O:O2 (66:33) and with 
sevoflurane.  
Standard monitoring included non invasive blood pressure monitoring, 
electrocardiogram, end tidal concentration of carbon dioxide and pulse 
oximetry.  
Intravenous fluids, Normal Saline and Ringer’s Lactate, were administered at 
the rate of 100 ml/hour. There was minimal blood loss in the surgery. 
All patients were given antiemetic ondansetron 4mg i.v. 
At the end of the surgery, patients were extubated after the reversal of the 
residual neuromuscular blockade with inj.neostigmine (0.05 mg/kg) and inj. 
glycopyrrolate (0.01 mg/kg). 
Postoperatively, whenever patients complained of pain (Visual Analog Score 
of more than 3) they received 0.5mic/kg of fentanyl as rescue analgesia, 
which was repeated until the pain subsided. 
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Pain quantification was done on a modified Visual Analog Scale Score 
between 0 and 10 (0 = no pain to 10 = worst imaginable pain.88 
 
Figure 10.1 Visual Analog Scale Scoring 
 
Sedation scores were based on Ramsay Sedation Scale. 
RAMSAY SEDATION SCALE74 
1— Patient anxious, agitated or restless or both 
2— Patient co-operative, oriented and tranquil 
3— Patient responds to commands only 
4— Patient sedated with brisk response to stimulus 
5— Patient sedated with sluggish response to stimulus 
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6— Patient sedated with no response to stimulus 
 [Stimulus indicates a light glabellar tap or loud command at ears] 
 
ANXIETY SCORES75 were given by 
1— fearful/afraid 
2— worried 
3— anxious 
4— uneasy 
5— calm and comfortable 
 
The pain scores, sedation scores, anxiety scores were recorded preoperatively, 
after extubation then at 1, 2, 4 and 6 hours. 
 
Baseline heart rate, systolic bloood pressure, diastolic blood pressure, mean 
arterial pressure, respiratory rate, saturation were recorded. Heart rate, 
systolic and diastolic blood pressure, mean arterial pressure were recorded 
preoperatively and during various time intervals intraoperatively and after 
extubation. 
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Postoperative blood pressure, heart rate, respiratory rate, postoperative pain, 
sedation, anxiety, total analgesic consumption were recorded at the end of 6 
hours.  
 
Side effects like nausea, vomiting, drowsiness, constipation and other 
complications, if any, were also recorded preoperatively, as well as 1, 2, 4 and 
6 hours after extubation. 
 
 
STATISTICAL ANALYSIS 
Sample size was estimated by conducting a pilot study in 5 patients. The 
sample size needed was 50 for the power of the study to be 50% and alpha 
erroe to be 0.05. hence, considering the drop outs the sample size was chosen 
as 75. 
The statistical analysis was done using SPSS software version 20. Qualitative 
analysis between the three groups was done by ANOVA and quantitative 
analysis by chi- square test. 
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OBSERVATION AND RESULTS 
 
The study was done in 75 patients of either sexes in the age group of 20 to 60 
years, belonging to ASA class-1 and ASA class- 2, undergoing elective 
lumbar laminectomy under general anaesthesia. 
 
The patients were categorised into three groups 
Group 1  -  placebo 
Group 2  -  tramadol 
Group 3  -  pregabalin 
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DEMOGRAPHIC PROFILES 
The demographic profiles like age, sex, weight, height, BMI, ASA status were 
comparable between the three groups as shown in table 11.1.  
 
Table 11.1 : Demographic  profiles of the three groups 
Demographic 
profile 
Group1 
(Mean±SD) 
 
Group 2 
(Mean±SD) 
 
 
Group3 
(Mean± SD) 
P value 
Age (years) 44.04 ± 7.44 44.12  ± 8.52 45.96 ± 8.5 0.645 
Sex (M:F) 8:17 9:16 8:17 0.942 
Weight (Kg) 56.44 ± 7.19 57.64 ± 7.49 56.88 ± 6.18 0.828 
Height (metre) 1.56 ± 0.07 1.57 ± 0.07 1.59 ± 0.09 0.404 
BMI (kg/m2) 23.35 ± 1.74 23.20 ± 2.04 22.53 ± 1.14 0.192 
ASA class 1:2 13:12 13:12 12:13 0.948 
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Figure 11.1: Comparison of demographic data among all the groups 
The mean age of patients in group1 is 44.04 with a standard deviation of 7.44 
and in group 2 the mean age is 44.12 with a standard deviation of 8.52 and in 
group 3 the mean age is 45.96 with a standard deviation of 8.5. The p value is 
0.645, which is insignificant. So all the three groups are comparable in terms 
of age. 
The mean weight of the patients in group 1 is 56.44 with a standard deviation 
of 7.19 and in group 2 are 57.44 with a standard deviation of 7.49 and in 
group 3 are 56.88 with a standard deviation of 6.18. The p value is found to 
be 0.828 which is not significant. Therefore the three groups are comparable 
in their weight.  
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The mean height of patients in group1, group 2 and group 3 are 1.56, 1.57and 
1.59 with a standard deviation of 0.07, 0.07 and 0.09 respectively. The p 
value is found to be 0.404 which is not significant. This implies that there is 
no significant difference in height among the three groups and they are 
comparable. 
The mean body mass index among group 1, group 2 and group 3 are 23.35, 
23.20 and 22.53 with a standard deviation of 1.74, 2.04 and 1.14 respectively. 
The p value is 0.192 which is not significant. Therefore the body mass index 
is comparable among all the three groups. 
 
 
Figure 11.2 Comparison of demographic data (gender distribution) 
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The figure 11.2 shows the gender distribution among all the three groups. The 
sex ratio (male:female) among group 1, group 2 and group 3 are 8:17, 9:16 
and 8:17 respectively. The p value is found to be 0.942 which is not 
significant which shows the gender distribution among all the three groups is 
comparable. 
 
 
Figure 11.3 Comparison of ASA status among all the groups 
 
The figure 11.3 shows the ASA status among all three groups. The ASA 
class1:2 ratios among the three groups 1, 2 & 3 are 13:12, 13:12 & 12:13 
respectively. The p value is found to be 0.948 which is not significant. This 
implies that the ASA status among all the three groups is comparable.  
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Table 11.2 Duration of surgery and Spinal levels 
 Group-1 
Mean±SD) 
Group-2 
(Mean±SD) 
Group-3 
(Mean±SD) 
P value 
Duration of 
surgery (minutes) 
148.00±15.00 144.80±11.3 146.40±17.29 0.63 
Spinal levels (1:2) 12:13 11:14 13:12 0.852 
 
The mean duration of surgery in minutes among group 1, group 2 and group 3 
are 148±15, 148.80±11.3 and 146.40±17.29 respectively. The p value is found 
to be 0.63 which is insignificant. This shows that the mean duration of 
surgery among the three groups is comparable. 
 
Figure 11.4 Mean duration of surgery among the three groups 
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The spinal levels of laminectomy (1:2) in group 1, group 2 and group 3 are 
12:13, 11:14 and 13:12 respectively with a p value of 0.852 which shows that 
the groups are comparable. 
 
 
Figure 11.5 Number of spinal segments operated among all the three 
groups 
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Table 11.3 Baseline hemodynamic parameters of the three groups  
Parameter Group-1 
(Mean±SD) 
Group-2 
(Mean±SD) 
Group-3 
(Mean±SD) 
P-value 
Heart rate 75.12  ± 4.49 74.84 ± 7.11 74.28 ± 6.60 0.422 
Systolic blood 
pressure 
122.00 ±11.09 122.24 ± 9.18 122.64 ±8.41 0.381 
Diastolic blood 
pressure 
78.92± 6.32 78.92 ± 9.10 78.04± 5.19 0.117 
Mean arterial  
blood pressure 
93.16± 7.64 93.24 ± 8.151 93.16 ± 5.41 0.101 
 
The mean baseline heart rate of group 1, group 2 and group 3 are 75.12±4.49, 
74.84±7.11 and 74.28±6.60 respectively with a p value of 0.422 which is 
insignificant. The mean baseline systolic blood pressures of group 1, group 2 
and group 3 are 122±11.09, 122.24±9.18 and 122.64±8.41 respectively with a 
p value of 0.381 which is not significant. The mean baseline diastolic blood 
pressure of group1, group 2 and group 3 are 78.92±6.32, 78.92±9.10 and 
78.04±5.19 respectively with a p value of 0.117 which is insignificant. The 
mean baseline MAP of group 1, 2 &3 are 93.16±7.64, 93.24±8.151and 
93.16±5.41 respectively with a p value of 0.101 which is insignificant. 
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Thus all three groups are comparable in their baseline hemodynamic 
parameters. 
 
 
 
Figure 11.6 Comparison of Baseline hemodynamic parameters among all 
the groups 
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Table 11.4 Comparison of Baseline hemodynamic parameters among 
group 1 & 2 
Parameter  Group 1 
(Mean±SD) 
Group  2 
(Mean±SD) 
Mean 
difference(1-2) 
 
p-value 
Heart rate 75.12  ± 4.49 74.84 ± 7.11 2.28 0.587 
Systolic blood 
pressure 
122.00±11.09 122.24±9.18 3.760 0.514 
Diastolic blood 
pressure 
78.92± 6.32 78.92 ± 9.10 3.120 0.368 
Mean Arterial  
blood pressure 
93.16 ± 7.64 93.24±8.151 3.720 0.212 
 
The p values of baseline heart rate, systolic blood pressure, diastolic blood 
pressure and mean arterial blood pressures between group 1 and 2 are 
insignificant and therefore the two groups are comparable 
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Table 11.5 Comparison of Baseline hemodynamic parameters between 
group 1 & 3  
Parameter  Group-1 
(Mean±SD) 
Group-3 
(Mean±SD)  
Mean 
difference(1-3) 
p-value 
Heart rate 75.12  ± 4.49 74.28 ± 6.60 0.840 1.000 
Systolic blood 
pressure 
122.00±11.09 122.64 ±8.41 0.640 1.000 
Diastolic blood 
pressure 
78.92± 6.32 78.04± 5.19 0.880 1.000 
Mean Arterial 
blood pressure 
93.16 ± 7.64 93.16 ± 5.41 0.000 1.000 
 
 
The above table shows the comparison of baseline hemodynamic variables 
between group 1 and 3. From the p values we know that group 1 and 3 are 
comparable.  
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Table 11.6 Trend in the heart rate  
Heart rate 
 
Group 1 
(Mean±SD) 
 
Group 2  
(Mean±SD) 
Group 3 
(Mean±SD) 
P value 
Pre-op 80.36± 5.65 78.08 ± 6.44 80.32± 7.22 0.366 
AI -1 min 90.52 ± 9.59 82.20± 5.06 82.48± 5.44 0.000# 
AI -3 min 87.64  ± 8.61 81.88± 8.38 82.88± 7.80 0.026# 
AI -5 min 81.44 ± 8.65 76.20 ± 7.19 77.76 ± 7.36 0.056 
30 min 81.48 ± 4.71 72.56 ± 5.95 75.32 ± 6.38 0.000# 
60 min 82.68 ± 5.23 71.36 ± 6.49 76.12 ± 7.02 0.000# 
120 min 81.48 ± 4.71 70.92 ± 6.78 77.32 ± 6.46 0.000# 
AE 97.76 ± 8.56 86.20 ± 6.81 91.68 ± 7.76 0.000# 
#- p value significant 
The mean heart rate changes during different time intervals in group 1, 2 & 3 
are shown in the above table. The p value appears to be significant in all the 
time intervals except preoperatively and five minutes after intubation. 
The groups are individually compared in the following tables. 
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Figure 11.7 Trend in the heart rate during various time intervals 
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Table 11.7 Heart rate changes between group 1& 2 during various time 
intervals 
 
HeartRate 
 
Group 1 
(Mean±SD) 
 
Group 2 
(Mean±SD) 
 
  
 
Mean difference 
(1-2) 
P value 
Pre-op 80.36± 5.65 78.08 ± 6.44 2.280 0.674 
AI -1 min 90.52 ± 9.59 82.20± 5.06 8.32 0.000# 
AI -3 min 87.64  ± 8.61 81.88± 8.38 5.760 0.050# 
AI -5 min 81.44 ± 8.65 76.20 ± 7.19 5.240 0.059 
30 min 81.48 ± 4.71 72.56 ± 5.95 8.920 0.000# 
60 min 82.68 ± 5.23 71.36 ± 6.49 11.320 0.000# 
120 min 81.48 ± 4.71 70.92 ± 6.78 10.560 0.000# 
AE 97.76 ± 8.56 86.20 ± 6.81 11.560 0.000# 
#- p value significant 
The comparison of heart rate changes between group 1 & 2 showed 
significant difference at 1 minute & 3 minutes after intubation and at 30, 60 
and 120 min and after extubation. 
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Table 11.8 Comparison of heart rate changes between group 1 & 3 at 
various time intervals 
Heart Rate 
 
Group 1 
(Mean±SD) 
 
Group 3 
(Mean±SD) 
Mean difference 
(1-3) 
P value 
Pre-op 80.36± 5.65 80.32± 7.22 0.040 1.000 
AI -1 min 90.52 ± 9.59 82.48± 5.44 8.040 0.010# 
AI -3 min 87.64  ± 8.61 82.88± 7.80 4.760 0.049# 
AI -5 min 81.44 ± 8.65 77.76 ± 7.36 3.680 0.294 
30 min 81.48 ± 4.71 75.32 ± 6.38 6.160 0.001# 
60 min 82.68 ± 5.23 76.12 ± 7.02 6.560 0.001# 
120 min 81.48 ± 4.71 77.32 ± 6.46 4.160 0.040# 
AE 97.76 ± 8.56 91.68 ± 7.76 6.080 0.001# 
# - p value significant 
The comparison of heart rate changes between group 1 & 3 showed 
significant difference at 1 and 3 minutes after intubation, at 30, 60 and 120 
minutes and after extubation. 
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Table 11.9 Trend in the systolic blood pressure  
SBP 
 
Group 1 
(Mean±SD) 
 
Group 2  
(Mean±SD) 
Group 3 
(Mean±SD) 
P value 
Pre-op 124.00 ± 11.09 119.04 ± 8.35 119.12±9.93 0.133 
AI-1 min 152.16 ± 22.09 125.04 ± 9.99 134.76 ± 15.64 0.000# 
AI-3 min 129.16 ± 14.59 115.92 ± 16.49 119.56±7.92 0.003# 
AI-5 min 122.28 ± 13.87 116.12 ± 9.19 116.64± 11.42 0.068 
30 min 118.96 ± 12.37 108.76 ± 8.07 112.28 ± 10.55 0.018# 
60 min 123.16 ± 12.16 111.00± 9.22 113.36 ± 10.41 0.007# 
120 min 119.96 ± 12.37 114.48± 8.74 115.48 ± 10.48 0.265 
AE 148.44 ± 20.61 117.28 ± 11.04 131.80 ± 15.71 0.000# 
#- p value significant 
From the above table it appears that the systolic blood pressure changes 
among the three groups at 1& 3 minute after intubation and at 30 min, 60 
minutes and after extubation is significant (p<0.05).   
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Figure 11.8 Trend in the systolic blood pressure among the three groups 
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Table 11.10 Systolic blood pressure changes between group 1 & 2 
SBP 
 
Group 1 
(Mean±SD) 
 
Group 2 
(Mean±SD) 
 
 
Mean difference 
(1-2) 
P value 
Pre-op 124.00 ±11.09 119.04 ± 8.35 4.960 0.238 
AI-1 min 152.16 ±22.09 125.04 ± 9.99 27.120 0.000# 
AI-3 min 129.16 ±14.59 115.92 ± 16.49 13.240 0.043# 
AI-5 min 122.28 ±13.87 116.12 ± 9.19 6.16 0.150 
30 min 118.96 ±12.37 108.76 ± 8.07 10.20 0.085 
60 min 123.16 ±12.16 111.00± 9.22 12.16 0.079 
120 min 119.96 ±12.37 114.48± 8.74 5.48 0.212 
AE 148.44 ±20.61 117.28 ± 11.04 31.160 0.000# 
# - p value significant 
 
The systolic blood pressure changes are significant between the groups 1 & 2 
at 1 and 3 minutes after intubation and after extubation (p< 0.05). 
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Table 11.11 Systolic blood pressure changes between group 1 & 3 
SBP 
 
Group 1 
(Mean±SD) 
 
Group 3 
(Mean±SD) 
Mean difference 
(1-3) 
P value 
Pre-op 124.00 ± 11.09 119.12±9.93 4.880 0.253 
AI-1 min 152.16 ± 22.09 134.76 ± 15.64 17.400 0.001# 
AI-3 min 129.16 ± 14.59 119.56±7.92 9.600 0.099 
AI-5 min 122.28 ± 13.87 116.64± 11.42 5.640 0.274 
30 min 118.96 ± 12.37 112.28 ± 10.55 6.680 0.100 
60 min 123.16 ± 12.16 113.36 ± 10.41 9.80 0.094 
120 min 119.96 ± 12.37 115.48 ± 10.48 4.48 0.278 
AE 148.44 ± 20.61 131.80 ± 15.71 16.640 0.002# 
# - p value significant 
           From the above table it is clear that the systolic blood pressure is significantly 
(p<0.05) decreased in group 3 when compared to group 1 at 1 minute after 
intubation and after extubation. In all other time intervals the mean systolic 
blood pressure in group 3 is less than that of group 1 but is insignificant     
(p>0.05). 
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Table 11.12 Trend in the diastolic blood pressure 
DBP 
 
Group 1 
(Mean±SD) 
 
Group 2  
(Mean±SD) 
Group 3 
(Mean±SD) 
P value 
Pre -op 78.28 ± 7.36 76.56 ± 9.38 77.44 ± 5.75 0.855 
AI-1 min 99.52 ± 14.44 84.20 ± 11.84 90.96± 10.51 0.000# 
AI-3 min 83.92 ± 9.88 75.56±11.96 80.20±11.26 0.033# 
AI-5 min 81.28 ± 9.82 76.80±7.33 79.72 ± 8.55 0.183 
30 min 73.52 ± 8.45 70.40±5.78 72.80 ± 5.78 0.270 
60 min 75.20 ± 8.40 71.44 ± 5.65 74.60±9.26 0.130 
120 min 73.52 ± 8.45 70.40 ± 9.42 72.40 ± 5.78 0.384 
AE 93.96 ± 21.65 79.88 ± 9.06 88.04 ± 11.02 0.006# 
#- p value significant 
The diastolic blood pressure of group 1, 2 & 3 is statistically significant at 1, 
3 minute after intubation and after extubation (p<0.05). 
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Figure 11.9 Trend in the diastolic blood pressure 
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Table 11.13 Diastolic blood pressure changes between group 1 & 2 
DBP 
 
Group 1 
(Mean±SD) 
 
Group 2  
(Mean±SD) 
Mean difference 
(1-2) 
P value 
Pre -op 78.28 ± 7.36 76.56 ± 9.38 01.72 1.000 
1 min 99.52 ± 14.44 84.20 ± 11.84 15.32 0.000# 
3 min 83.92 ± 9.88 75.56±11.96 08.36 0.028# 
5 min 81.28 ± 9.82 76.80±7.33 04.48 0.211 
30 min 73.52 ± 8.45 70.40±5.78 03.12 0.518 
60 min 75.20 ± 8.40 71.44 ± 5.65 03.76 0.293 
120 min 73.52 ± 8.45 70.40 ± 9.42 03.12 0.521 
AE 93.96 ± 21.65 79.88 ± 9.06 14.08 0.004# 
# - p value significant 
The mean diastolic blood pressure of group 2 is significantly decreased than 
that of group 1 at 1 & 3 minute after intubation and after extubation (p<0.05). 
In all other time intervals there is no significant decrease between the two 
groups. 
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Table 11.14 Diastolic blood pressure changes in group 1and 3 
DBP 
 
Group 1 
(Mean±SD) 
 
Group 3 
(Mean±SD) 
Mean difference 
(1-3) 
P value 
Pre -op 78.28 ± 7.36 77.44 ± 5.75 00.84 1.000 
1 min 99.52 ± 14.44 90.96± 10.51 08.56 0.049# 
3 min 83.92 ± 9.88 80.20±11.26 03.72 0.716 
5 min 81.28 ± 9.82 79.72 ± 8.55 01.56 1.000 
30 min 73.52 ± 8.45 72.80 ± 5.78 00.72 1.000 
60 min 75.20 ± 8.40 74.60±9.26 00.60 1.000 
120 min 73.52 ± 8.45 72.40 ± 5.78 01.12 1.000 
AE 93.96 ± 21.65 8.04 ± 11.02 09.92 0.040# 
# - p value significant 
The mean diastolic blood pressure of group 3 is significantly less (p<0.05) in 
group 3 when compared to group 1 at 1 minute after intubation and after 
extubation. The difference in mean diastolic blood pressure is insignificant 
between group 1 & 3 in rest of the time intervals. 
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Table 11.15 Trend in the mean arterial blood pressure 
MAP 
 
 
Group 1 
(Mean±SD) 
 
Group 2 
(Mean±SD) 
 
 
Group 3 
(Mean±SD) 
P value 
Pre-op 93.28 ± 7.70 90.12 ± 8.57 91.60 ± 9.77 0.365 
1 min  117.48 ± 18.07 97.08 ± 9.15 104.40 ± 13.38 0.000# 
3 min 98.36 ± 11.05 87.64 ± 9.25 88.44 ± 13.30 0.011# 
5 min 94.24 ± 10.40 87.88 ± 7.87 88.44 ± 9.15 0.050 
30 min 86.88± 9.68 82.64± 7.88 83.88± 6.38 0.117 
60 min 88.16 ± 9.17 80.66± 8.22 84.72± 6.63 0.038 
120 min 86.60± 9.39 82.40 ± 8.34 84.80± 6.58 0.519 
AE 114.16 ± 16.20 91.68± 8.93 102.44± 12.14 0.000# 
# - p value significant 
 
The mean arterial blood pressure between group 1, 2 and 3 shows significant 
difference at 1 and 3 minutes after intubation and after extubation. 
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Figure 11.10 Trend in the mean arterial blood pressure 
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Table 11.16 Mean arterial blood pressure changes in group 1 & 2 
MAP 
 
Group 1 
(Mean±SD) 
 
Group 2 
(Mean±SD) 
 
 
Mean difference 
(1-2) 
P value 
Pre-op 93.28 ± 7.70 90.12 ± 8.57 03.160 1.000 
1 min  117.48 ± 18.07 97.08 ± 9.15 20.400 0.000# 
3 min 98.36 ± 11.05 87.64 ± 9.25 10.720 0.044# 
5 min 94.24 ± 10.40 87.88 ± 7.87 06.360 1.000 
30 min 86.88 ± 9.68 82.64 ± 7.88 04.240 1.000 
60 min 88.16 ± 9.17 80.66 ± 8.22 07.500 0.821 
120 min 86.60 ± 9.39 82.40 ± 8.34 04.200 1.000 
AE 114.16 ± 16.20 91.68 ± 8.93 22.480 0.000# 
# - p value significant 
 
The mean arterial pressure in group 2 is less than that of group 1 in all the 
time intervals but is significantly less at 1 and 3 minutes after intubation and 
after extubation 
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Table 11.17 Mean arterial blood pressure changes in group 1 and 3 
MAP 
 
Group 1 
(Mean±SD) 
 
Group 3 
(Mean±SD) 
Mean difference 
(1-3) 
P value 
Pre-op 93.28 ± 7.70 91.60 ±9.77 01.680 0.663 
1 min  117.48 ± 18.07 104.40 ± 13.38 13.080 0.005# 
3 min 98.36 ± 11.05 88.44 ± 13.30 09.920 0.051 
5 min 94.24 ± 10.40 88.44 ± 9.15 05.800 0.087 
30 min 86.88 ± 9.68 83.88 ± 6.38 03.000 0.582 
60 min 88.16 ± 9.17 84.72 ± 6.63 03.440 0.409 
120 min 86.60 ± 9.39 84.80 ± 6.58 01.800 1.000 
AE 114.16 ± 16.20 102.44 ± 12.14 11.720 0.005# 
# - p value significant 
 
The mean arterial pressure in group 3 is significantly decreased at 1 minute 
after intubation and after extubation while there is no significant difference in 
mean arterial blood pressure between the groups in rest other time intervals. 
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Table 11.18 Pain scores in the three groups 
VAS 
 
Group 1 
(Mean±SD) 
 
Group 2 
(Mean±SD) 
 
 
Group 3 
(Mean±SD) 
P value 
Pre-op 1.52 ± 0.510 0.68± 0.476 1.48± 0.510 0.000# 
AE  4.84± .624 1.48± .510 3.12 ± 0.332 0.000# 
1 hr 5.52± 0.510 2.00± 0.408 2.84± 0.374 0.000# 
2 hr 6.48± 0.510 2.40± 0.500 3.40± 0.500 0.000# 
4 hr 5.80± 0.408 2.32± 0.476 4.12± 0.332 0.000# 
6 hr 5.72 ± 0.458 2.52 ± 0.510 4.08± 0.277 0.000# 
# - p value significant 
 
The mean Visual Analog Scale scoring in group 2 is less than group 3, which 
is less than group 1. This difference is significant (p<0.05)  
 
 
 
83 
 
 
Figure 11.11 Pain scores in the three groups at different time intervals 
 
Table 11.19 Pain scores in group 1 and group 2 
VAS 
 
Group 1 
(Mean±SD) 
 
Group 2 
(Mean±SD) 
 
 
Mean difference 
(1-2) 
P value 
Pre-op 1.52 ± 0.510 0.68± 0.476 0.840 0.000# 
AE  4.84± .624 1.48± .510 3.360 0.000# 
1 hr 5.52± 0.510 2.00± 0.408 3.520 0.000# 
2 hr 6.48± 0.510 2.40± 0.500 4.080 0.000# 
4 hr 5.80± 0.408 2.32± 0.476 3.480 0.000# 
6 hr 5.72 ± 0.458 2.52 ± 0.510 3.200 0.000# 
# - p value significant 
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The pain scores in group 2 is less than group 1 preoperatively, after 
extubation and 1, 2, 4 & 6 hours postoperatively and this difference is 
significant (p<0.05) 
 
Table 11.20 Pain scores between group 1 and group 3 
VAS 
 
Group 1 
(Mean±SD) 
 
Group 3 
(Mean±SD) 
Mean difference 
(1-3) 
P value 
Pre-op 1.52 ± 0.510 1.48± 0.510 0.040 1.000 
AE  4.84± 0.624 3.12 ± 0.332 1.720 0.000# 
1 hr 5.52± 0.510 2.84± 0.374 2.680 0.000# 
2 hr 6.48± 0.510 3.40± 0.500 3.080 0.000# 
4 hr 5.80± 0.408 4.12± 0.332 1.680 0.000# 
6 hr 5.72 ± 0.458 4.08± 0.277 1.640 0.000# 
# - p value significant 
The mean pain scores in group 3 is significantly less (p<0.05) than group 1 
after extubation and 1, 2, 4 and 6 hours postoperatively. 
 
 
 
85 
 
Table 11.21 Pain scores in group 2 and 3  
VAS 
 
Group 2 
(Mean±SD) 
 
 
 
Group 3 
(Mean±SD) 
Mean difference 
(2-3) 
P value 
Pre-op 0.68± 0.476 1.48± 0.510 0.800 0.000# 
AE  1.48± .510 3.12 ± 0.332 1.640 0.000# 
1 hr 2.00± 0.408 2.84± 0.374 0.840 0.000# 
2 hr 2.40± 0.500 3.40± 0.500 1.000 0.000# 
4 hr 2.32± 0.476 4.12± 0.332 1.800 0.000# 
6 hr 2.52 ± 0.510 4.08± 0.277 1.560 0.000# 
# - p value significant 
The pain scores in group 2 are lower than that of group 1 which is significant. 
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Table 11.22 Anxiety scores in the three groups 
AS 
 
Group 1 
(Mean±SD) 
 
Group 2 
(Mean±SD) 
 
 
Group 3 
(Mean±SD) 
P value 
Pre-op 1.84± 0.37 0.20 ± 0.41 1.16 ± 0.37 0.000# 
AE  1.72 ± 0.46 0.48± 0.51 1.16 ± 0.37 0.000# 
1 hr 2.80± 0.41 0.40± 0.50 1.60± 0.50 0.000# 
2 hr 3.52± 0.51 0.56± 0.51 1.96± 0.20 0.000# 
4 hr 3.32± 0.48 0.60± 0.50 1.60± 0.50 0.000# 
6 hr 3.32± 0.48 0.64 ± 0.49 1.64± 0.49 0.000# 
# - p value significant 
The mean anxiety scores in group 2 is less than group 3 which is less than 
group 1 and this difference is statistically significant. 
 
Figure 11.12 Anxiety scores in the three groups at different time intervals 
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Table 11.23 Anxiety scores in group 1 & 2 
AS 
 
Group 1 
(Mean±SD) 
 
Group 2 
(Mean±SD) 
 
 
Mean difference 
(1-2) 
P value 
Pre-op 1.84 ± 0.37 0.20 ± 0.41 1.640 0.000# 
AE  1.72 ± 0.46 0.48 ± 0.51 1.240 0.000# 
1 hr 2.80 ± 0.41 0.40 ± 0.50 2.400 0.000# 
2 hr 3.52 ± 0.51 0.56 ± 0.51 2.960 0.000# 
4 hr 3.32 ± 0.48 0.60 ± 0.50 2.720 0.000# 
6 hr 3.32 ± 0.48 0.64 ± 0.49 2.680 0.000# 
# - p value significant 
The mean anxiety scores in group 2 is less than that of group 1 preoperatively,   
after extubation and 1, 2, 4 and 6 hours after extubation. This difference is 
statistically significant. 
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Table 11.24 Anxiety scores between group 1 & 3 
AS 
 
Group 1 
(Mean±SD) 
 
Group 3 
(Mean±SD) 
Mean difference 
(1-3) 
P value 
Pre-op 1.84± 0.37 1.16 ± 0.37 0.680 0.000# 
AE  1.72 ± 0.46 1.16 ± 0.37 0.560 0.000# 
1 hr 2.80± 0.41 1.60± 0.50 1.200 0.000# 
2 hr 3.52± 0.510 1.96± 0.20 1.560 0.000# 
4 hr 3.32± 0.48 1.60± 0.50 1.720 0.000# 
6 hr 3.32± 0.48 1.64± 0.49 1.680 0.000# 
# - p value significant 
The mean anxiety score in group 3 is lesser than that of group 1 and this 
difference is statistically significant. 
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Table 11.25 Anxiety scores between group 2 & 3 
AS 
 
Group 2   
(Mean±SD) 
 
 
 
Group 3 
(Mean±SD) 
 
Mean difference 
(2-3) 
P value 
Pre-op 0.20 ± 0.41 1.16 ± 0.37 0.960 0.000# 
AE  0.48± 0.51 1.16 ± 0.37 0.680 0.000# 
1 hr 0.40± 0.50 1.60± 0.50 1.200 0.000# 
2 hr 0.56± 0.51 1.96± 0.20 1.400 0.000# 
4 hr 0.60± 0.50 1.60± 0.50 1.000 0.000# 
6 hr 0.64 ± 0.49 1.64± 0.49 1.000 0.000# 
# - p value significant 
The mean anxiety scores in group 3 is less than that of group 1 which is 
statistically significant. 
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Table 11.26 Sedation scores in the three groups 
RSS 
 
Group 1 
 
 
Group 2 
 
 
 
Group 3 
 
P value 
Pre-op 1.00± 0.00 2.32± 0.48 1.52± 0.51 0.000# 
AE  1.28 ± 0.46 2.64 ± 0.49 2.48± 0.51 0.000# 
1 hr 1.48± 0.51 3.60± 0.51 3.52± 0.50 0.000# 
2 hr 1.48± 0.51 3.80 ± 0.41 3.52 ± 0.51 0.000# 
4 hr 1.56 ± 0.51 3.92± 0.28 3.44± 0.51 0.000# 
6 hr 1.60± 0.50 3.72± 0.46 3.40± 0.50 0.000# 
# - p value significant 
The sedation score in group 2 is greater than that of group 3 which is greater 
than that of group 1 preoperatively, after extubation and 1, 2, 4 and 6 hours 
postoperatively. 
 
Figure 11.13 Ramsay sedation score in the three groups 
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Table 11.27 Sedation scores in group 1& 2 
RSS 
 
 
 
Group 1 
(Mean±SD) 
 
Group 2 
(Mean±SD) 
 
 
Mean difference 
(1-2) 
P value 
Pre-op 1.00± 0.00 2.32 ± 0.48 1.320 0.000# 
AE  1.28 ± 0.46 2.64 ± 0.49 1.360 0.000# 
1 hr 1.48± 0.51 3.60± 0.51 2.120 0.000# 
2 hr 1.48± 0.51 3.80 ± 0.41 2.320 0.000# 
4 hr 1.56 ± 0.51 3.92± 0.28 2.360 0.000# 
6 hr 1.60± 0.50 3.72± 0.46 2.120 0.000# 
# - p value significant 
 
The sedation score in greater in group 2 than in group 1 with a statistically 
significant difference in all time intervals 
 
 
 
 
92 
 
Table 11.28 Sedation scores in group 1 & 3 
RSS 
 
Group 1 
(Mean±SD) 
 
Group 3 
(Mean±SD) 
Mean difference 
(1-3) 
P value 
Pre-op 1.00± 0.00 1.52 ± 0.51 0.520 0.000# 
AE  1.28 ± 0.46 2.48 ± 0.51 1.200 0.000# 
1 hr 1.48± 0.51 3.52± 0.50 2.040 0.000# 
2 hr 1.48± 0.51 3.52 ± 0.51 2.040 0.000# 
4 hr 1.56 ± 0.51 3.44± 0.51 1.880 0.000# 
6 hr 1.60± 0.50 3.40± 0.50 1.800 0.000# 
# - p value significant 
The sedation score in group 3 is significantly greater than group 1 in all the 
time intervals 
  
93 
 
Table 11.29 Sedation scores in group 2 & 3 
RSS 
 
Group 2 
(Mean±SD) 
 
 
 
Group 3 
(Mean±SD) 
 
Mean difference 
(2-3) 
P value 
Pre-op 2.32 ± 0.48 1.52 ± 0.51 0.800 0.000# 
AE  2.64 ± 0.49 2.48 ± 0.51 0.160 0.746 
1 hr 3.52± 0.51 3.60± 0.50 0.080 1.000 
2 hr 2.80 ± 0.41 3.52 ± 0.51 0.720 0.000# 
4 hr 2.92± 0.28 3.44± 0.51 0.520 0.000# 
6 hr 2.72± 0.46 3.40± 0.50 0.680 0.000# 
# - p value significant 
The mean sedation score in group 2 is significantly greater than that of    
group 3 preoperatively and 2, 4 and 6 hours postoperatively. Immediately 
after extubation and 1 hour after extubation sedation score in group 3 is 
comparable to that of group 2. 
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Table 11.30 Mean fentanyl requirement in the 3 groups 
 Group 1 
(Mean±SD) 
Group 2 
(Mean±SD) 
Group 3 
(Mean±SD) 
P 
value 
Fentanyl 
requirement 
(micrograms) 
128.80±17.40 40.40±9.17 60.40±17.29 0.004# 
# - p value significant 
The mean fentanyl requirement in group 1 is 128±17.40, in group 2 is 
40.40±9.17 and in group 3 it is 60.40±17.29. Fentanyl requirement is more in 
group 1 compared to group 3, which itself is more than group 2. These 
differences are statistically significant. 
 
Figure 11.14 Fentanyl requirements among the three groups 
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Table 11.31 Adverse effects in the three groups 
 Group 1 
 N(%) 
Group 2  
N (%) 
Group 3 
 N (%) 
Nausea  2 (8%) 5 (20%)  1 (4%) 
Vomiting 3 (12%) 5 (20%) 1 (4%) 
Drowsiness  1 (4%) 8 (32%) 1 (4%) 
 
From the above table it is clear that the adverse effects like nausea, vomiting 
and drowsiness in group 3 is less than that of group 1 and group 2 
 
Figure 11.15 Complications among the three groups 
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DISCUSSION 
 
In the present study, the pain scores of the patients who received tramadol and 
pregabalin were significantly decreased in comparison to placebo group. The 
tramadol group had the least pain scores when compared to the pregabalin and 
placebo groups.  
It was also observed that the analgesia provided by tramadol was superior to 
that of pregabalin, but pregabalin was more effective in reducing the pain 
when compared to placebo. 
The amount of rescue analgesia required was more in control group and hence 
the total dose of fentanyl given during the first six hours of the postoperative 
period was relatively more when compared to tramadol and pregabalin 
groups. 
In a study by Pandey CK ET al.68 fentanyl requirement is decreased in 
patients undergoing lumbar discectomy in gabapentin group. Similar results 
were obtained by Turan A et al.89 for spinal surgeries. Pandey CK et al.69 used 
600mg gabapentin and obtained similar results. Turan An et al.90 found a 
decrease in tramadol comsumption in patients who were given gabapentin for 
abdominal hysterectomy. In other studies by Fassoulaki A et al.28, Jokela R et 
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al.48 and Gianesello et al.34 opioid consumption is decreased as with above 
studies. 
Hence, the opioid sparing effect of pregabalin as per my study is in agreement 
with the above studies.68, 89, 69, 90, 28, and 35 
Pregabalin has previously been shown to have good analgesic efficacy in 
patients with postherpetic neuralgia1, spinal cord injury92, gynaecological 
surgery48, dental surgery43 and in patients following lumbar laminectomy and 
discectomy67. However, the doses in these studies varied from 75 mg to 300 
mg per day. 
In this study, the anxiety scores in pregabalin and tramadol groups were 
significantly lower when compared to the placebo group. However, the 
anxiety scores were significantly lower in the pregabalin group in comparison 
to the placebo group, whereas it is significantly higher than the tramadol 
group. This observation shows that pregabalin also has an anxiolytic effect 
additionally, although it is to a lesser extent when compared to tramadol. 
Ozgencil E et al.67 in their study found that pregabalin 300 mg per day and 
gabapentin 1200 mg per day had more analgesic, anxiolytic and also opioid 
sparing effects. Patient satisfaction is also high and is also more effective in 
preventing postoperative shivering than the placebo following lumbar 
laminectomy and discectomy. 
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Menigaux C et al62 in their study concluded that premedication with 
gabapentin 1200mg improved preoperative anxiolysis, postoperative 
analgesia and early knee mobilization after arthroscopic anterior cruciate 
ligament repair. 
The above two studies67,62 show the anxiolytic effect of pregabalin which is in 
line with my study. 
The preoperative sedation scores in my study were significantly greater in 
tramadol group when compared to the pregabalin and placebo groups. After 
extubation and postoperatively the level of sedation increased in both 
pregabalin and tramadol. However, this increase in sedation in pregabalin 
group was more after extubation and 1 hour postoperatively (but less than 
tramadol insignificantly) ; rest all the time intervals it was significantly lower 
than the tramadol group though the sedation was significantly higher than the 
placebo group.  
From this, we infer that pregabalin has a good anxiolytic effect without 
resulting in excessive sedation. 
Yoon MH et al.102 in their animal study, administered gabapentin intrathecally 
to rats. In their study they concluded that spinally delivered gabapentin has no 
effect on resting heart rate or blood pressure. But it attenuated the enhanced 
pain behaviour and cardiovascular response otherwise produced by the injury. 
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Van Den Berg AA et al.95 studied the obtundation of stress response to 
laryngoscopy and intubation by opioids. In this study they found that the 
increase in heart rate (1 minute after intubation) that occurred with 
laryngoscopy and intubation is not attenuated by tramadol but rather it 
returned at a faster rate to baseline in tramadol group (5 minutes after 
intubation) when compared to placebo group (7 minutes after intubation). 
In my study, the increase in heart rate is significantly lower in tramadol group 
while compared to placebo at 1 and 3 minutes after intubation and at 30, 60 
and 120 minutes and after extubation. The decrease in heart rate is 
insignificant preoperatively and 5 minutes after intubation. 
 Similarly in the pregabalin group, the increase in heart rate is significantly 
lower at 1 & 3 minutes after intubation, at 30, 60 & 120 minutes and after 
extubation when compared to the placebo group.   
The systolic blood pressure, diastolic blood pressure and mean arterial blood 
pressure in the tramadol group is significantly lower when compared to 
placebo group at 1 & 3 minutes after intubation and after extubation. In 
pregabalin group the systolic, diastolic and mean arterial blood pressure are 
significantly lower at 1 minute after intubation and after extubation. 
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Thus both pregabalin and tramadol given preoperatively, apart from 
preventing pressor response to laryngoscopy and intubation also helps to 
maintain a stable hemodynamics throughout surgery. 
Drowsiness was less frequent in the pregabalin group (4%) compared to the 
tramadol group (32%). Fewer patients had nausea (4%) and vomiting (4%) 
with pregabalin when compared to placebo (nausea 8%, vomiting 12%) and 
tramadol (nausea 20%, vomiting 20%). This implies that the incidence of 
nausea and vomiting is more with tramadol and placebo than with pregabalin. 
Edwards JE et al.27studied the efficacy of oral tramadol and tramadol with 
acetaminophen combination for acute postoperative pain. According to their 
study the adverse effects with tramadol were dizziness, drowsiness, nausea, 
vomiting and headache. 
Moore RA et al.65 did a meta-analysis to assess the safety and efficacy of oral 
tramadol when compared with standard analgesics. They found that the 
adverse effects with tramadol were greater at higher doses due to dose-
response effect. 
In a study by Ozgencil et al.67 it was found that pregabalin is well tolerated at 
all doses and has higher patient satisfaction. 
All these studies67,27,74 are in agreement with my study regarding the adverse 
effects of pregabalin and tramadol. 
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SUMMARY 
 
This prospective, randomised, single blinded placebo-controlled study 
evaluated the efficacy of preoperative administration of pregabalin and 
tramadol for postoperative pain management in patients undergoing lumbar 
laminectomy. 
Seventy five patients belonging to ASA1 and 2, between 20 to 60 years of 
either sex, satisfying inclusion criteria were randomised into three groups 
containing 25 patients each. 
Group 1– placebo 
Group 2 – tramadol 
Group 3 – pregabalin 
These drugs were administered to the patients 1 hour before anaesthetic 
induction. The heart rate, systolic blood pressure, diastolic blood pressure, 
mean arterial blood pressure were recorded preoperatively(baseline and 1 
hour after drug administration), intraoperatively and postoperatively. 
Respiratory rate and saturation were also recorded preoperatively and 
postoperatively. Pain scores, anxiety scores, sedation scores were recorded 1 
hour after drug administration, after extubation and postoperatively. Fentanyl 
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consumption in the postoperative period and any adverse effects were also 
noted. The data was analysed using SPSS software version 20. The 
demographic profiles of the three groups were matched and the baseline 
hemodynamic variables in all three groups were comparable. 
The pain scores and anxiety scores were significantly reduced in pregabalin 
and tramadol groups when compared to the placebo group but the reduction in 
scores in the pregabalin group is significantly less than that of the tramadol 
group. The sedation score is higher in tramadol group when compared to 
placebo and pregabalin; however, there was no significant difference in 
sedation between pregabalin and tramadol immediately after extubation and at 
1 hour postoperatively. The sedation scores remained significantly higher in 
the pregabalin group when compared to the placebo group. 
Further the systolic, diastolic and mean arterial blood pressures were 
significantly lower in the tramadol group when compared to the placebo 
group at 1 & 3 minute after intubation and after extubation whereas in 
pregabalin group these parameters were significantly lower than placebo 
group at 1 minute after intubation and after extubation. Heart rate changes in 
tramadol and pregabalin groups were significantly lower than the placebo 
group at 1 & 3 minutes after intubation and at 30, 60 and 120 minutes and 
after extubation. 
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The mean requirement of fentanyl is significantly lower in pregabalin and 
tramadol groups when compared to placebo group. Side effects in tramadol 
and placebo group were significantly higher than the pregabalin group. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
104 
 
CONCLUSION 
 
The following conclusions can be drawn from the study. 
Pregabalin has a statistically significant effect when compared to placebo, but 
this effect is less when compared to tramadol. 
The need for rescue analgesia is least in tramadol patients followed by 
pregabalin and it increases maximum in the placebo group. 
Pregabalin has a statistically significant anxiolytic effect when compared to 
the placebo group. 
The anxiolytic effect of pregabalin is associated with less sedation when 
compared to that of tramadol. 
Pregaalin reduces the pressor response to laryngoscopy and intubation and 
also maintains a stable hemodynamics similar to tramadol. 
Pregabalin has lowest number of postoperative complications like nausea, 
vomiting and drowsiness when compared to tramadol. 
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PATIENT CONSENT FORM 
 
Study title:  “A Prospective, randomized, placebo-controlled study evaluating 
the effectiveness of oral pregabalin and tramadol for postoperative pain 
management in patients undergoing lumbar laminectomy”. 
                                        
 
Study centre:    INSTITUTE OF ANAESTHESIOLOGY AND CRITICAL CARE ,                           
                                MADRAS MEDICAL COLLEGE & GOVT GENERAL HOSPITAL, 
                                CHENNAI 600003. 
         
Participant name:                     Age:                         Sex:               I.P.no:               
 
                  
I confirm that I have understood the purpose of procedure for the above 
study. I have the opportunity to ask the question and all my questions and 
doubts have been answered to my satisfaction. 
                      
I have been explained about the pitfall in the procedure.  I have been 
explained about the safety, advantage and disadvantage of the technique. 
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I understand that my participation in the study is voluntary and that I 
am free to withdraw at anytime without giving any reason. 
 
I understand that investigator, regulatory authorities and the ethics 
committee will not need my permission to look at my health records both in 
respect to current study and any further research that may be conducted in 
relation to it, even if I withdraw from the study. I understand that my identity 
will not be revealed in any information released to third parties or published, 
unless as required under the law. I agree not to restrict the use of any data or 
results that arise from the study. 
 
        
 
Date:                                                 Signature / thumb impression of patient: 
 
Place:                                                                                            Patient name: 
 
 
Signature of the investigator: 
 
Name of the investigator: 
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PROFORMA 
 
NAME:                                                                                 DATE:                                                                                                     
AGE/SEX:                                                IP.NO: 
SPINAL LEVELS:                                                               GROUP:                                                     
DURATION OF SURGERY:                                               ASA:                                                                                                       
Ht:     cms                                                                              MMS: 
Wt:    kgs                                                                                                               
PRE OP ASSESSMENT: 
HISTORY:    H/O Co-morbid illness 
                       H/O Allergy 
                      H/O any medications 
PREMEDICATION: 
Pregabalin/ Tramadol/ Placebo:                                           TIME: 
INDUCTION TIME: 
SKIN INCISION TIME: 
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SKIN CLOSURE TIME: 
 
PARAMETERS 
 
 
BL 
 
PREOP 
 
AI-1 
MIN 
 
AI-3 
MIN 
 
AI-5 
MIN 
 
30 
MIN 
 
60 
MIN 
 
120 
MIN 
HR /min         
SBP mmHg         
DBP mmHg          
MAP mmHg         
 
PARAMETERS PREOP AE 1 HR 2 HR 4 HR 6 HR 
VAS score       
Anxiety score       
Sedation score       
 
POSTOPERATIVE  FENTANYL  CONSUMPTION (micrograms): 
 
ADVERSE  EFFECTS: nausea/ vomiting/ drowsiness: 
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MASTER CHART 
S.NO NAME AGE SEX Wt.[KG] Ht.[mts] BMI[KG/M2] GROUP ASA 
BASELINE PARAMETERS 
DURATION  
SPINAL 
LEVELS HR SBP DBP MAP 
1 USHA 35 F 50 1.52 22.22 1 1 72 116 68 84 150 2 
2 BANUMATHI 37 F 45 1.5 20 1 2 72 140 86 104 140 1 
3 ANJALAI 48 F 60 1.53 25.63 1 2 80 136 88 104 130 2 
4 VALLI 43 F 48 1.51 21 1 1 78 134 81 98 140 1 
5 GOPALAKRISHNAN 44 M 67 1.65 24.6 1 2 74 110 70 83 120 2 
6 THANGARAJ 49 M 68 1.66 24.6 1 1 86 126 80 95 160 1 
7 KUPPU 39 F 65 1.58 26.43 1 2 71 120 78 91 130 1 
8 CHINNAKULANTHAI 46 F 52 1.5 23.11 1 1 70 124 82 95 150 2 
9 DURAI 45 M 56 1.67 20 1 2 76 110 71 83 140 1 
10 MALLIGA 48 F 52 1.5 23.11 1 1 76 124 83 96 140 2 
19 VIJI 43 F 51 1.51 22.36 1 1 79 120 70 86 140 1 
20 LAKSHMI 52 F 50 1.54 21 1 1 68 106 71 82 150 2 
21 PITCHAIKANNI 40 M 56 1.5 24.8 1 1 76 132 78 95 160 1 
22 SANDHYA 32 F 50 1.45 23.78 1 1 82 140 82 101 150 2 
23 POOVAN 54 M 65 1.65 23.87 1 2 75 142 84 103 180 2 
24 SUMITHA 58 F 50 1.5 22.22 1 2 71 118 72 87 140 1 
25 SELVI 60 F 55 1.69 22.6 1 2 78 128 82 97 150 2 
26 KRISHNAVENI 46 F 50 1.52 22.22 2 1 65 120 74 89 150 1 
27 GOVINDHASAMY 54 M 45 1.5 20 2 2 82 132 81 97 140 1 
28 JAYANTHI 56 F 60 1.53 25.63 2 2 71 113 69 83 120 2 
29 DEVAKI 60 F 48 1.51 21 2 1 72 120 70 86 140 2 
30 MENAKA 58 F 67 1.65 24.6 2 2 69 112 70 83 150 1 
31 ANBALAGAN 36 M 56 1.55 23.3 2 1 66 130 84 99 140 1 
32 VIGNESH 37 M 48 1.53 20.5 2 2 83 142 91 107 120 1 
33 SAMPATH 32 M 68 1.66 24.6 2 1 72 123 79 93 150 2 
34 NASREEN 56 F 54 1.56 22.1 2 1 73 130 80 96 140 2 
35 LALITHA KUMARI 44 F 63 1.67 22.58 2 2 70 122 80 93 130 2 
36 SHEELA DEVI 45 F 46 1.48 21 2 1 84 110 64 79 140 2 
37 NIRMALA 48 F 59 1.52 25.5 2 2 68 122 71 87 120 1 
38 ROSEMARY 42 F 56 1.49 25.22 2 2 86 110 59 75 120 2 
39 SELVARAJ 40 M 68 1.64 25.2 2 1 76 110 60 76 150 1 
40 BALAMMAL 39 F 65 1.58 26 2 1 86 120 80 93 150 1 
41 RAMAMOORTHY 45 M 52 1.5 23.11 2 2 76 102 72 81 140 1 
42 GNANASUNDARI 56 F 66 1.64 25.2 2 2 60 132 78 95 140 1 
43 INBALAKSHMI 33 F 53 1.55 22 2 1 73 114 66 81 150 2 
44 KASILINGAM 36 M 66 1.58 26.43 2 1 68 128 68 87 160 2 
45 GANAPATHY 39 M 57 1.53 24.34 2 1 71 120 68 85 150 2 
46 CHANDRAKUMARI 40 F 69 1.68 24.44 2 2 64 128 86 99 130 1 
47 SUGANTHI 49 F 61 1.63 22.95 2 2 68 120 93 101 140 2 
48 ESWARI 38 F 58 1.66 21 2 1 80 112 82 91 130 2 
49 PARVATHY 32 F 56 1.67 20 2 2 68 112 82 91 130 2 
50 JANAKIRAM 42 M 50 1.54 21 2 1 70 122 66 84 140 2 
51 SENGINI 33 M 53 1.5 23.55 3 1 84 136 78 97 150 2 
52 BABU 45 M 46 1.49 20.7 3 2 76 140 77 98 150 1 
53 MURUGESAN 38 M 49 1.46 22.9 3 1 68 117 83 94 120 2 
54 SAROJA 60 F 52 1.51 22.8 3 2 70 110 76 87 120 1 
55 SHANTHINI 44 F 55 1.55 24.44 3 1 86 129 91 102 150 2 
56 JAYARAM 52 M 52 1.48 23.73 3 1 78 124 80 94 140 1 
57 PACHAMUTHU 49 M 56 1.56 23 3 2 76 119 77 91 150 2 
58 RAMANUJAM 58 M 51 1.51 22.36 3 1 76 114 75 88 140 1 
59 NAGAMMAL 50 F 65 1.66 23.58 3 2 86 123 86 98 150 1 
60 SOLIAMMAL 52 F 58 1.55 24.14 3 1 84 116 74 88 130 2 
61 SIVARAMAN 40 M 59 1.63 22.2 3 2 76 132 80 97 160 1 
62 SABBOO 44 F 52 1.52 22.5 3 2 70 122 82 95 150 1 
63 AMUDHA 37 F 56 1.57 22.7 3 2 60 126 84 98 150 1 
64 AMEER BASHA 58 M 60 1.68 21.25 3 2 74 130 80 96 150 1 
65 VIJAYLAKSHMI 55 F 53 1.54 22.34 3 1 73 130 78 95 180 2 
66 MEENA 57 F 68 1.72 22.9 3 2 74 124 78 93 140 2 
67 MENAKA 43 F 66 1.75 21.55 3 2 68 108 70 82 140 1 
68 MARUTHAYE 44 F 50 1.6 19.5 3 2 76 110 76 87 160 2 
69 KANNIAMMAL 42 F 56 1.58 22.4 3 1 71 121 78 92 180 1 
70 CHARU 46 F 60 1.68 21.25 3 2 78 129 84 99 140 1 
71 SRIVIDHYA 38 F 53 1.54 22.34 3 1 64 130 82 98 180 2 
72 JANAKI 32 F 68 1.72 22.9 3 2 70 126 84 98 150 2 
73 MADHU 38 F 66 1.75 21.55 3 1 68 122 81 94 140 1 
74 SUBHA 36 F 56 1.58 22.4 3 1 71 116 68 84 120 2 
75 VISALAKSHI 58 F 62 1.6 24.21 3 1 80 112 71 84 120 2 
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HEART RATE SYSTOLIC BLOOD PRESSURE 
PREOP AI 1MIN AI 3 MIN AI 5MIN  3OMIN 60 MIN 
120 
MIN AE PREOP 
AI- 
1MIN 
 AI- 
3MIN AI- 5MIN 30 MIN 60 MIN 120 MIN AE 
83 84 88 82 78 76 78 95 116 142 118 116 120 118 120 139 
80 82 82 76 76 74 76 91 140 134 119 109 142 140 142 133 
86 92 102 98 84 82 84 102 136 162 131 116 124 122 124 148 
92 92 88 82 80 82 80 96 134 199 149 117 117 115 117 186 
79 84 81 76 76 78 76 92 110 133 125 122 95 93 95 142 
92 89 92 80 90 92 90 108 126 162 135 126 119 121 119 158 
74 79 72 74 76 74 76 88 120 128 112 116 116 118 116 121 
74 79 71 76 80 82 80 94 124 142 128 118 116 118 116 139 
78 82 86 82 80 82 80 88 110 102 101 92 90 92 90 101 
78 74 86 92 78 80 78 94 124 144 124 162 112 114 112 139 
85 86 82 74 72 74 72 99 120 171 141 118 112 114 112 162 
74 75 84 76 88 90 88 92 106 109 111 118 102 104 102 105 
82 86 85 71 86 88 86 96 132 163 131 141 99 101 99 157 
84 81 98 87 85 87 85 109 140 165 111 121 110 112 110 152 
79 78 92 86 75 77 75 110 142 169 158 131 127 129 127 171 
75 80 98 89 88 90 88 112 118 167 139 127 116 118 116 159 
84 88 89 77 86 84 86 101 128 151 119 121 130 132 130 148 
71 85 73 71 68 66 62 86 110 128 120 121 122 124 118 110 
79 113 99 87 80 82 80 107 129 136 126 136 130 132 128 120 
77 87 87 73 70 72 70 84 117 120 116 118 117 118 112 100 
71 81 74 71 74 70 72 81 118 126 117 118 122 120 124 122 
73 85 76 73 74 72 70 85 114 112 114 120 114 116 112 110 
72 89 74 70 68 66 64 83 120 138 130 136 132 134 128 120 
80 92 89 80 80 82 80 88 139 146 136 146 140 142 138 130 
78 80 80 74 72 70 72 80 137 130 126 128 127 128 122 132 
72 82 78 70 70 71 70 78 128 136 127 128 122 136 134 132 
74 84 80 72 73 72 70 81 124 122 124 130 124 126 122 136 
89 102 81 82 78 80 81 88 100 118 110 116 112 112 108 100 
74 83 71 72 70 71 70 82 119 126 116 126 120 122 118 100 
92 93 88 89 82 80 82 90 114 117 114 114 110 114 110 118 
82 84 78 74 74 73 72 80 108 116 107 108 112 110 110 112 
92 112 96 88 88 84 85 100 110 128 120 126 122 124 118 110 
81 93 86 88 74 73 74 92 104 102 104 110 104 106 103 100 
74 92 78 62 62 60 60 90 130 130 128 132 128 131 126 122 
78 85 70 72 70 68 71 84 115 113 112 122 115 114 110 112 
71 82 74 76 68 64 66 80 131 136 128 134 130 132 126 118 
76 94 96 81 72 70 70 90 125 128 122 126 124 122 120 128 
71 84 79 71 65 64 64 80 126 134 124 126 120 134 132 136 
79 106 95 88 66 64 65 90 122 120 122 128 122 124 120 118 
88 103 90 75 78 74 75 92 116 120 116 116 112 116 112 120 
78 84 80 71 66 62 60 80 110 114 108 110 114 112 116 114 
80 88 82 75 72 74 68 84 112 130 122 128 124 126 120 112 
89 89 81 82 84 85 87 102 119 147 125 119 128 126 128 139 
84 86 79 72 78 80 82 90 122 109 97 112 99 101 103 106 
74 72 71 72 70 72 74 83 103 122 135 136 95 93 95 114 
82 84 77 73 72 71 79 88 110 121 94 93 107 109 111 117 
92 91 88 89 80 82 80 93 129 152 112 118 130 132 135 146 
82 80 76 78 78 79 81 88 114 148 107 109 101 103 105 142 
82 80 78 74 78 79 81 84 117 125 91 115 113 111 113 125 
86 84 80 76 88 90 82 92 112 156 110 101 100 102 105 148 
92 94 96 88 83 81 83 112 122 164 159 133 111 109 111 159 
94 89 94 92 74 72 73 92 109 124 121 117 101 103 105 126 
81 84 86 88 70 68 70 93 132 136 112 114 127 129 131 138 
76 79 77 74 64 62 63 88 116 126 101 103 99 101 103 126 
64 72 78 62 76 78 80 92 129 147 131 141 120 122 125 132 
79 82 88 86 70 72 73 86 128 148 124 119 123 125 127 148 
78 82 70 72 70 68 69 85 133 147 127 124 124 122 124 151 
80 86 74 76 68 70 71 92 121 134 110 112 118 116 118 127 
71 76 74 76 80 82 81 82 110 114 101 108 103 105 107 110 
74 78 75 76 73 71 73 80 110 119 102 101 108 110 112 114 
76 80 96 81 80 82 84 94 112 128 114 120 111 113 115 126 
82 87 84 80 66 68 70 97 126 136 118 126 121 123 125 138 
71 76 79 71 74 76 74 84 128 142 110 114 118 120 122 133 
75 79 78 69 70 72 74 91 128 132 129 118 119 121 123 128 
79 82 95 88 70 72 74 106 118 158 149 132 121 123 125 165 
78 81 83 74 83 85 87 95 112 127 102 110 108 110 112 129 
88 82 90 75 84 86 88 103 116 107 117 121 102 105 107 108 
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DIASTOLIC BLOOD PRESSURE MEAN ARTERIAL PRESSURE 
PREOP 
 AI-1 
MIN  AI- 3MIN 
 AI- 5 
MIN 30 MIN 60 MIN 120MIN AE PREOP 
AI- 1 
MIN 
AI-3 
MIN 
AI-5 
MIN 30 MIN 60 MIN 
120 
MIN AE 
76 101 82 76 77 75 77 99 89 114 94 89 91 89 91 112 
80 78 67 72 87 89 87 74 97 96 78 81 107 105 105 93 
86 120 96 81 86 88 86 108 98 134 107 92 98 99 98 121 
66 115 92 81 75 77 75 108 77 164 111 91 86 89 88 134 
77 103 95 89 65 67 65 102 84 111 103 99 72 75 74 115 
88 116 98 86 77 79 77 113 97 131 109 97 89 92 90 128 
71 86 71 70 76 78 76 82 86 100 84 85 89 91 89 95 
82 98 84 78 74 76 74 89 95 112 98 91 88 89 87 105 
62 69 66 63 54 56 54 68 74 80 78 73 66 67 65 79 
69 80 78 113 70 72 70 82 85 101 93 126 84 85 83 101 
70 108 87 79 62 64 62 19 87 129 105 92 78 80 78 126 
69 80 77 81 65 67 65 79 83 89 88 93 77 79 77 87 
74 102 87 90 63 65 63 99 92 122 101 107 75 76 74 118 
71 92 74 78 69 71 69 94 86 116 86 92 82 84 82 114 
84 106 92 87 80 82 80 105 102 127 114 101 95 97 95 127 
71 111 94 86 72 74 72 110 86 129 109 99 86 88 86 126 
82 96 78 83 76 78 76 93 96 114 91 95 94 95 93 111 
77 101 82 82 72 74 76 72 87 109 94 94 88 90 89 84 
82 105 92 84 80 82 78 84 97 115 103 101 96 98 94 95 
71 84 72 76 70 72 68 77 86 95 86 89 85 87 82 84 
72 79 72 74 68 70 66 79 87 94 86 88 85 86 85 93 
74 72 80 84 72 74 70 80 87 85 91 95 85 87 83 89 
87 91 92 92 82 84 80 82 97 106 104 106 98 100 95 94 
92 95 102 94 90 92 88 94 107 111 113 111 106 108 104 105 
81 94 82 80 80 82 78 87 99 105 96 95 95 97 92 101 
82 89 82 82 78 80 76 89 97 104 96 97 92 98 95 103 
84 82 80 84 82 84 80 90 97 95 94 99 95 97 93 105 
61 71 70 72 62 64 60 62 73 86 83 86 78 79 75 74 
72 75 82 74 70 72 68 74 87 91 93 91 86 88 84 82 
61 74 62 66 60 62 58 67 78 88 79 81 76 79 75 83 
62 69 62 64 58 60 56 69 77 84 76 78 75 76 73 83 
77 62 70 74 62 64 60 70 87 83 86 91 81 83 79 83 
75 95 80 80 70 72 68 70 84 97 87 89 81 83 79 79 
80 95 90 82 78 80 76 82 96 106 102 98 94 96 92 95 
68 81 70 72 68 70 66 75 83 91 83 88 83 84 80 87 
70 76 70 72 66 68 64 76 90 95 89 92 87 89 84 89 
72 70 78 82 70 72 68 78 89 89 92 96 87 88 85 94 
88 92 95 95 86 86 88 86 100 105 104 105 97 101 102 102 
94 96 104 96 92 94 90 96 103 103 109 106 101 103 99 103 
84 96 84 82 82 84 80 90 94 103 94 93 91 94 90 99 
84 91 84 80 80 82 78 92 92 98 91 89 91 91 90 99 
64 70 68 70 64 66 70 76 79 89 85 89 83 85 86 87 
76 93 70 69 74 72 74 91 90 111 88 85 92 89 91 107 
83 72 62 74 62 60 62 67 95 84 73 86 74 73 75 80 
67 83 96 94 66 64 66 81 79 96 109 108 75 73 75 92 
74 91 65 66 77 75 77 90 86 101 75 75 87 86 88 99 
90 101 72 81 85 83 85 97 102 116 81 89 96 99 101 113 
74 107 74 76 68 70 68 103 87 121 85 87 79 80 80 116 
75 79 48 83 72 70 72 76 89 74 60 90 85 83 85 92 
76 108 81 67 65 67 65 99 88 124 91 78 77 78 78 115 
86 107 102 93 75 77 75 104 98 126 121 106 87 87 86 122 
72 83 68 72 63 65 63 86 84 96 82 82 75 77 76 99 
82 96 79 76 76 78 76 94 989 109 90 88 93 94 94 108 
74 94 79 78 68 70 68 93 88 104 86 86 78 80 79 105 
84 96 92 88 70 72 70 92 99 113 105 105 86 88 88 105 
79 95 80 78 63 65 63 92 95 112 95 92 83 84 84 110 
78 98 84 82 74 76 74 96 96 114 98 96 90 91 90 114 
76 89 71 74 74 76 74 86 91 104 84 86 88 89 88 99 
68 78 68 70 67 69 67 74 82 90 79 82 79 80 80 86 
72 78 73 68 72 74 72 65 84 91 82 79 84 85 85 81 
78 90 78 76 73 75 73 90 89 102 90 70 85 87 86 102 
82 94 74 76 72 74 72 93 96 108 88 92 88 90 89 108 
84 92 68 74 71 73 71 94 98 108 82 87 86 88 87 107 
84 88 84 80 78 80 78 86 98 102 99 92 91 93 92 100 
77 103 90 81 70 72 70 101 90 121 109 98 87 88 88 122 
71 90 58 72 64 66 64 84 84 102 72 84 78 80 79 99 
74 69 73 72 61 63 61 67 88 81 87 88 74 76 76 80 
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VISUAL ANALOG SCORE ANXIETY SCORE RAMSAY SEDATION SCORE 
PREOP AE  1 HR 2 HR 4 HR 6 HR PREOP AE 1 HR 2 HR 4 HR 6 HR PREOP AE 1 HR 2 HR 4 HR 6 HR 
2 5 6 6 5 6 2 2 3 3 3 3 1 1 1 1 2 2 
2 5 6 7 6 5 2 1 2 3 3 3 1 2 2 2 1 1 
1 4 5 6 6 6 1 1 3 4 4 4 1 1 2 1 1 2 
2 4 5 6 6 6 2 2 3 3 3 3 1 1 1 2 1 1 
1 5 6 7 6 6 2 2 3 4 3 3 1 1 2 1 2 2 
1 5 5 6 5 5 2 2 2 3 3 3 1 1 1 2 1 1 
1 5 5 7 6 6 1 1 3 4 4 4 1 2 2 1 2 2 
2 6 6 7 6 5 2 2 3 3 3 4 1 2 1 2 2 1 
2 5 5 6 6 6 2 2 3 4 3 3 1 1 1 1 2 2 
2 5 5 7 6 6 2 2 3 3 3 3 1 1 2 2 2 1 
1 3 5 6 6 6 2 1 3 4 3 3 1 1 1 1 2 2 
1 5 6 7 6 5 2 2 3 3 3 3 1 1 2 1 2 2 
2 5 6 6 6 6 2 2 3 4 4 3 1 1 1 1 2 1 
1 5 6 7 6 6 2 2 3 4 4 4 1 1 1 1 2 2 
2 5 6 6 6 6 2 2 3 4 3 3 1 1 1 2 1 2 
1 5 6 7 6 6 2 2 2 4 4 3 1 2 2 2 1 2 
1 5 6 7 6 6 2 2 3 4 4 4 1 1 1 2 1 1 
0 1 2 3 2 3 0 0 0 1 0 1 2 3 3 3 3 3 
0 1 2 2 3 3 0 0 0 1 1 1 2 3 4 3 3 3 
1 2 2 3 2 2 0 0 0 1 1 0 3 2 4 2 3 2 
1 1 2 3 3 3 0 0 0 0 0 1 2 2 3 3 3 3 
1 2 2 2 2 2 1 1 0 1 0 1 2 3 4 3 3 3 
1 1 2 2 2 3 0 1 1 0 0 0 2 2 3 3 3 3 
1 2 2 3 3 2 1 0 1 1 1 1 2 3 4 3 3 3 
0 1 2 2 2 3 0 1 0 1 0 0 2 2 3 3 3 2 
1 2 2 2 2 2 1 0 1 0 0 0 2 3 4 3 2 3 
0 1 2 2 2 3 0 0 0 1 1 1 2 3 4 3 3 3 
0 2 2 2 2 3 1 1 0 0 1 0 3 3 3 2 3 3 
1 1 2 2 3 3 1 1 1 0 0 1 2 2 3 3 3 3 
1 2 2 3 2 3 0 1 1 1 1 1 2 3 4 2 3 2 
0 1 2 2 2 2 0 0 0 1 1 1 3 3 3 3 3 3 
0 2 1 2 2 3 0 0 1 1 1 0 3 2 4 3 3 2 
0 2 1 3 3 2 0 1 0 1 1 1 2 3 3 2 2 2 
1 1 3 3 3 3 0 0 0 1 1 1 3 3 4 3 3 3 
1 2 3 2 2 3 0 1 1 0 1 0 2 2 4 3 3 2 
1 2 2 2 2 3 0 0 0 1 1 1 2 3 3 3 3 3 
1 1 2 3 3 2 0 0 0 0 1 0 3 3 3 3 3 3 
1 1 2 2 2 2 0 1 0 0 0 0 2 3 3 3 3 3 
1 1 2 2 2 2 0 1 1 0 1 1 2 3 4 3 3 3 
1 2 2 3 3 2 0 1 1 0 0 1 3 2 4 3 3 3 
1 1 2 2 2 2 0 1 1 0 1 1 3 2 4 3 3 3 
1 2 2 3 2 2 0 0 0 1 0 1 2 3 3 2 3 2 
1 3 3 3 4 4 1 1 2 2 1 2 1 2 4 3 3 3 
2 3 3 3 4 4 1 1 1 2 2 2 2 3 3 4 4 4 
1 3 3 3 4 4 1 1 2 2 2 1 1 2 4 3 3 3 
2 3 3 3 4 4 2 1 1 2 2 1 2 2 4 3 4 4 
1 3 2 3 4 4 1 1 2 2 1 2 1 2 4 3 3 3 
2 3 3 4 4 4 2 2 2 2 2 1 1 2 4 4 3 4 
1 3 3 3 4 4 2 1 1 2 2 2 1 2 3 3 4 3 
2 3 2 4 4 5 1 2 1 2 1 1 2 3 4 4 3 4 
1 3 3 3 4 4 1 1 2 2 2 2 1 3 4 3 4 3 
2 4 3 4 4 4 1 1 1 2 1 2 1 2 3 4 3 4 
1 4 3 3 4 4 1 1 2 2 2 1 2 3 4 3 4 3 
2 3 3 4 4 4 1 2 1 2 1 2 2 2 3 4 3 3 
1 4 3 4 4 4 1 1 1 2 2 2 2 3 4 3 4 4 
1 3 2 4 5 4 1 1 2 2 1 2 2 3 4 4 3 3 
2 3 3 3 4 5 1 1 1 2 1 1 2 2 4 4 4 3 
2 3 3 4 5 4 1 1 2 2 2 2 2 3 4 3 3 4 
1 3 3 3 4 4 1 1 2 2 2 1 2 2 3 4 3 3 
2 3 3 3 4 4 1 2 2 2 2 2 2 3 4 4 4 4 
1 3 3 4 4 4 2 1 2 2 2 1 1 3 4 3 3 3 
2 3 3 3 4 4 1 1 2 2 2 2 1 2 3 4 4 3 
1 3 3 3 4 4 1 1 1 1 1 2 1 3 3 3 3 4 
2 3 3 3 4 4 1 1 2 2 2 2 2 2 4 4 3 3 
1 3 2 3 4 4 1 1 2 2 1 2 1 3 3 3 3 3 
2 3 3 4 4 4 1 1 2 2 1 1 2 3 3 4 4 3 
1 3 3 4 5 4 1 1 1 2 2 2 1 2 3 4 4 4 
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FENTANYL[µg] 
COMPLICATIONS 
NAUSEA VOMITING DROWSINESS 
150 A A A 
140 A A A 
160 A A A 
150 A A A 
160 A P A 
160 A A A 
150 A A A 
140 A A A 
170 A A A 
200 A P P 
160 A A A 
160 A P A 
170 A A A 
160 P A A 
200 A A A 
180 A A A 
190 A A A 
10 A A A 
10 A A A 
20 A A A 
20 A P P 
40 A A P 
40 A A A 
30 A A P 
30 A A P 
30 P A A 
20 A A A 
20 A A A 
30 P A A 
40 A A P 
20 A A P 
20 A A A 
30 P P A 
20 A A A 
20 A A A 
40 A A P 
30 A A P 
20 P A A 
20 A P A 
20 A A A 
20 A P A 
10 P P A 
60 A A A 
50 A A A 
60 A A A 
30 A A A 
70 A A P 
80 A A A 
60 A A A 
40 A A A 
40 A P A 
30 A A A 
50 A A A 
40 A A A 
60 A A A 
50 A A A 
70 A A A 
40 P A A 
40 A A A 
60 A A A 
50 A A A 
60 A A A 
40 A A A 
50 A A A 
30 A A A 
50 A A A 
60 A A A 
 
